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             INFECTIONS AND IMMUNOMODULATION IN LIVER  
                                     TRANSPLANT PATIENTS 
 
INTRODUCTION: 
        Liver Transplantation is the surgical replacement of diseased liver with the 
healthy liver from another person (allograft). It is a standard life saving 
procedure for many end stage liver diseases and acute liver diseases. According 
to the United Network for Organ Sharing (UNOS) in the United States, a total 
of 6331 liver transplantations were performed during 2008-2009, with a 
survival rate of 85% at one year. Survival rate after liver transplantation has 
improved over the years, due to advances in surgical techniques and a reduction 
in allograft rejection produced by new potent immunosuppressive agents. 
Inspite of use of protective barriers, antimicrobial prophylaxis, and vaccination, 
infections still represent a major cause of morbidity and mortality after liver 
transplantation. The opportunistic infections are the leading cause of death 
during the first three years after liver transplantation. The diagnosis of these 
infections are delayed because of potent immunosuppressive therapy that 
diminishes inflammatory responses and the clinical signs of infection may be 
absent or blunted, leading to delayed diagnosis and treatment.
1
 The risk of 
infection is determined by the intensity of exposure to infectious agents and the 
overall level of immunosuppression. The infections after liver transplantation 
may be acquired, reactivation of latent infection in the recipient, donor 
transmitted diseases and nosocomial.  
                 The incidence of infection is found to be 80% in liver transplant 
recipients and among them, the most common infection is bacterial (70%), 
followed by viral (20%) and fungal (8%) infection.
2
 The bacterial infection  
occurs with the highest incidence during the first month after transplantation 
and most commonly involve the surgical site, the abdominal cavity, blood 
stream, urinary tract and the respiratory system. The common bacterial 
infections are Enterococcus, Viridans Streptococci, Staphylococcus aureus and 
members of the Enterobacteriaceae family and there is an increasing trend 
towards antimicrobial resistance patterns among bacteria.
2
 
                 Among the opportunistic viral infections, the most common are the 
members of herpes virus group, of which Cytomegalovirus infection is the most 
common infection followed by Epstein-barr virus infection, Herpes simplex 
virus (HSV) 1 & 2 and Varicella Zoster infection. The fungal infections are 
most commonly caused by the Candida species followed by Aspergillus species. 
Cryptococcus neoformans occur less commonly in the form of meningitis, lung 
disease and cellulitis. Endemic mycoses due to Histoplasma capsulatum, 
Coccidiodes immitis and Blastomyces dermatidis may occur in liver transplant 
recipients from endemic regions. The infection due to Pneumocystis jirovecii 
occurs, primarily as diffuse bilateral pneumonitis and the use of trimethoprim- 
sulfamethoxazole prophylaxis has remarkably reduced its incidence after liver 
transplantation.
1
 
           Immunosuppressive agents are required in solid organ transplantation for 
induction and maintenance of immunosuppression or for the treatment of organ 
rejection. Usually, a corticosteroid in combination with a calcineurin inhibitors 
(CNI), alone or with an antimetabolite, mycophenolate mofetil (MMF) is started 
early to maintain immunosuppression to prevent transplant rejection. 
Corticosteroids have been used for induction of immunosuppression since the 
first successful cases of solid organ transplantation. Intravenous injection of 
corticosteroid is administered in high doses during the first few days after 
transplantation (usually 3 days) in combination with at least one  
immunosuppressant agent. It is then rapidly tapered over the first week to 
relatively low doses, 10 to 20 mg daily and are usually maintained in 
immunosuppression for atleast, 3 to 6 months after transplantation.
3
 The 
introduction of the two CNIs, Cyclosporine A (in 1970s and early 1980s) and 
tacrolimus (in 1990s) as immunosuppressant agents, greatly improved the 
outcome of Liver transplantation. Tacrolimus is superior to cyclosporine A in 
increasing patient and graft survival. Acute graft rejection and steroid resistant 
rejection episodes are less common with tacrolimus use during the first year 
after transplantation compared with cyclosporine A. The trough level 
monitoring of tacrolimus is done for dose adjustments to prevent toxicity. The 
major advantage in using, Mycophenolate mofetil is their lack of renal toxicity. 
In patients with pre-existing renal disease, they have been used in conjunction 
with low dose CNIs with promising results.
4
  
           More recently, antibody therapies have been combined with 
corticosteroids or used to facilitate “steroid-free” regimens. The use of 
antibodies that specifically inhibit or deplete recipient T-cells has been reported 
to decrease acute rejection episodes in the liver allograft. It also provides an 
opportunity to decrease the dose of other immunosuppressive agents such as 
corticosteroids and calcineurin inhibitors. This “steroid-free” protocol may be 
beneficial for patients with hepatitis C patients and for those with diabetes and 
hypertension. Antibody induction along with delayed CNI introduction can be 
used to reduce renal dysfunction in those with impairment. There was no 
significant increase in adverse side effects in solid organ transplant recipients 
receiving antibody induction.
3
 
 
 
 
 
 
AIM & OBJECTIVES: 
AIM: 
      To determine the common organisms that cause infections in liver transplant 
patients and the role of immunosuppressants in immunomodulation in liver 
transplant patients. 
OBJECTIVES: 
1) To compare the incidence of alcoholic cirrhosis with non- alcoholic 
cirrhosis indicated for liver transplantation. 
2) To identify the common organisms that cause infections in liver 
transplant patients. 
3) The antibiotic sensitivity pattern of the pathogen isolated. 
4) To evaluate the role of immunosuppressants in immumomodulation in 
liver transplant patients. 
 
 
 
 
 
 
                                 REVIEW OF LITERATURE 
HISTORY: 
          Liver transplantation is the treatment of choice for patients with cirrhosis, 
decompensated liver disease, acute liver failure and hepatocellular carcinoma. 
In 1963 March 1st, Thomas Starzl in Denver did the first liver transplantation in 
the world on a 3yr old boy with biliary atresia and the boy died during the 
surgery because of coagulation disorder and uncontrolled bleeding. The first 
successful human liver transplant was performed by Thomas Starzl in Denver in 
1967 on an 18 month old child with unresectable hepatoblastoma, at the 
university of Colorado, who survived more than 1 year.  
            In 1979, Calne used cyclosporine in two patients who had undergone 
liver transplantation for the first time, launching a new step in history of liver 
transplantation. In 1990, Starzl reported the first use of tacrolimus in patients 
submitted to liver transplantation, who suffered a rejection even after 
conventional immunosuppressive treatment. Currently, more than 10,00,000 
liver transplantations have been performed in the world so far.
7
 The first 
successful deceased liver transplantation in India was done  in 1998 followed by 
first successful living donor transplantation in November 1998 both done by 
Dr.Rajasekar.
8
 
 INDICATIONS FOR LIVER TRANSPLANTATION:
9
 
   (A) Acute liver failure:  
        1) Viral hepatitis A / hepatitis C 
         2) Intoxication - Paracetamol poisoning, 
         3) Wilsons disease, 
         4) Budd chiari syndrome. 
   (B) Chronic liver failure (Non-cholestatic cirrhosis): 
        1) Hepatitis B / hepatitis C 
        2) Autoimmune hepatitis, 
        3) Alcohol induced cirrhosis 
 (C) Chronic liver failure (Cholestatic cirrhosis): 
      1) Primary biliary cirrhosis (PBC) 
      2) Primary sclerosing cholangitis (PSC) 
      3) Secondary biliary cirrhosis 
 (D) Chronic liver failure (Metabolic): 
     1) Wilson’s disease 
     2) Hemochromatosis 
     3) α-1 Antitrypsin deficiency 
     4) Amyloidosis 
     5) Cystic fibrosis 
     6) Tyrosinemia 
(E) Chronic liver failure (Vascular): 
    1) Budd–Chiari syndrome 
(F) Other Indications: 
    1) Primary oxalosis 
    2) Gycogen storage diseases 
    3) Hyperlipidemia 
    4) Polycystic liver disease  
(G) Malignant diseases: 
    1) Hepatocellular carcinoma (HCC, within Milan criteria) 
    2) Fibrolamellar carcinoma (FLC) 
    3) Hepatoblastoma 
    4) Epitheloid hemangioendothelioma 
    5) Cholangiocellular adenocarcinoma 
    6) Neuroendocrine liver metastases 
(H) Benign liver tumors: 
     1) Adenomatosis 
(I) Liver transplantation in pediatric patients: 
    1) Biliary atresia 
    2) Byler’s disease 
    3) Alagille’s syndrome 
    4) Neonatal hepatitis/neonatal viral hepatitis 
    5) Autoimmune hepatitis 
   6) Hepatoblastoma. 
CONTRAINDICATIONS FOR LIVER TRANSPLANTATION: 
  (A) Absolute contraindications:    
      1) Active alcohol abuse                 
      2) Uncontrolled systemic infections      
      3) Uncontrolled extrahepatic malignancy  
      4) Uncontrolled / limiting medical conditions  
 (B) Relative contraindications:  
      1) Psychosocial conditions  
      2) Advanced age  
      3) Severe hepato-pulmonary or severe hepato-renal syndrome  
      4) Severe obesity/malnutrition 
 
INDICATIONS FOR LIVER TRANSPLANTATION: 
1) Viral Hepatitis: 
      Hepatitis viruses A, B and C cause the majority of viral hepatitis.  
(A) Hepatitis A Virus (HAV): 
            HAV belongs to the Picornaviridae family, is an RNA virus of 7.5kb 
size and a diameter of 27 nm. It has one serotype but multiple genotypes. The 
virus spreads from person to person most commonly via the faecal-oral route. 
The incubation period of is 15-45 days (average, 4 weeks). The virus is excreted 
in stool during the first few weeks of infection, before the onset of symptoms. 
Young children are usually asymptomatic. Acute hepatitis A is a more severe 
form and has higher mortality in adults than in children. The symptoms of acute 
infection are fever, malaise, anorexia, nausea, vomiting, hepatomegaly and 
elevated aminotransferase levels. Jaundice develops in more severe cases. The 
detection of immunoglobulin M (IgM) for hepatitis A, is the standard for 
diagnosing acute infection. The infection is usually self-limited and provides 
lifelong immunity. It does not lead to chronic infection and less than 1% of 
cases result in fulminant hepatic failure (FHF).
10
 
(B) Hepatitis B Virus (HBV): 
          HBV, belong to the Hepadnaviridae family, is a partially doubled-
stranded DNA virus and 3.2 kb size. It has 8 genotype (A-H). The virus consists 
of a nucleocapsid, HBcAg, which surrounds HBV DNA and DNA polymerase. 
The nucleocapsid is coated with HBsAg and the intact HBV virion is known as 
the Dane particle. The HBcAg is not detected in the circulation.
10
 HBV is 
transmitted by both parenterally by transfusion of blood or blood products, 
intravenous drug abuse with shared needles, hemodialysis, and needlestick 
injury in healthcare workers and also sexually. The incubation period is 30-180 
days (average 12 weeks). In acute infection, the symptoms are fever, malaise, 
nausea, vomiting, jaundice and right upper quadrant pain. About 5% of adult 
patients, 30-50% of infected children develop chronic infection.
10
 In chronic 
infection, fatigue is the most common symptom. Patient have abnormal liver 
function test and the detection of Ig M for hepatitis B core antigen (HBcAg) in 
serum is required for the diagnosis of acute infection. Hepatitis B surface 
antigen (HBsAg) may be present in acute infection or in patients who are 
chronic carriers (> 6 months). At present, the antiviral treatment is given for the 
inhibition of viral replication and to prevent or delay the progression of chronic 
hepatitis to cirrhosis or hepatocellular carcinoma. The drugs currently used for 
chronic infection include pegylated interferon α-2a and the nucleoside 
analogues, lamivudine and adenofovir. Globally, an estimated 30% of cases of 
cirrhosis and 45% of cases of HCC are attributed to HBV infection.
11
 
(C) Hepatitis C Virus (HCV): 
             HCV, belong to the Flaviviridae family, is a RNA virus with 9.4 kb size 
and 55 nm diameter. It has one serotype, but six major genotypes and more than 
80 subtypes. The virus is transmitted through transfusion of infected blood or 
blood products, transplantation of organs from infected donors and sharing of 
contaminated needles among IV drug users.
11,13
 The incubation period is 15- 45 
days (8 weeks ). Acute infections are usually asymptomatic and donot develop 
jaundice. About 55-85% of infected patients, remain viremic and may develop 
chronic liver disease.
13
 In chronic hepatitis C, patients may or may not be 
symptomatic with fatigue being the predominant symptom and 
aminotransferases may be elevated. The infection can be confirmed by serologic 
assays to detect antibody to HCV (anti-HCV) or with molecular tests 
(Qualitative PCR) for the presence of viral particles. For patients with chronic 
HCV infection, combination therapy with pegylated interferon and the antiviral 
drug, ribavirin are given for patients with moderate or severe inflammation or 
fibrosis. About 15-30% of patients with chronic hepatitis C progress to 
cirrhosis
13
 and this may take decades. Patients with HCV induced cirrhosis are 
also at increased risk for the development of  hepatocellular carcinoma 
especially with HBV co-infection.  
2) Alcoholic liver disease: (ALD) 
          It is caused by of increased alcohol consumption, leading to fatty liver, 
alcoholic hepatitis leading to fibrosis and cirrhosis. Alcohol is metabolized by 
alcohol dehydrogenase into acetaldehyde, then further metabolized by aldehyde 
dehydrogenase into acetic acid, which is finally oxidized into carbon dioxide 
and water. This process generates increased NADH that induces fatty acid 
synthesis and a decreased NAD level that results in decreased fatty acid 
oxidation. Subsequently, the increased fatty acids combine with glycerol to 
form triglycerides and accumulate, resulting in fatty liver. Alcoholic hepatitis is 
characterized by the inflammation of hepatocytes called as alcoholic steato- 
hepatitis and predispose to liver fibrosis. Cirrhosis is a late stage of liver disease 
characterised by inflammation, fibrosis and ending in scarring and necrosis.
14
 
About 10% to 20% of heavy alcohol drinkers will develop cirrhosis of the liver. 
Symptoms include jaundice, hepatomegaly and right upper quadrant pain. Late 
complications of cirrhosis include portal hypertension, coagulation disorders, 
ascites, encephalopathy and the hepato-renal syndrome. Fatty change and 
alcoholic hepatitis are reversible by abstinence and the later stages of fibrosis 
and cirrhosis are irreversible. Liver transplantation is the only definitive therapy 
for cirrhosis and the patient should be abstinent from alcohol consumption for 6 
months prior to transplantation.
15
 
3) Primary Biliary Cirrhosis: (PBS) 
           It is a chronic cholestatic liver disease. It is characterised by destruction 
of small intrahepatic bile ducts, which results in fibrosis and cirrhosis .The 
serological marker of primary biliary cirrhosis is the anti-mitochondrial 
antibody (AMA) and is identified in 95% of patients with primary biliary 
cirrhosis. These patients usually have fatigue and pruritus. Other auto-
antibodies such as antinuclear antibody are also identified. Anti-Sp100 and anti-
gp210 have a high specificity for primary biliary cirrhosis and is helpful, when 
AMA is negative and its presence is associated with clinically more aggressive 
disease. Liver biopsy is helpful, when AMA is absent and the biochemical 
profile shows a mixed cholestatic and hepatocellular pattern. Ursodeoxycholic 
acid (UDCA) plays a major role in the treatment. The Liver transplantation is a 
life-saving surgery for those with decompensated cirrhosis with excellent 
outcome.
17
 
 4) Budd-Chiari Syndrome: (BCS) 
           It is a very rare condition caused by thrombotic occlusion of the hepatic 
vein. It may be primary or secondary depending on the origin of the obstructive 
lesion. It is caused by blockage of two or more major hepatic veins that increase 
the sinusoidal pressure and reduces sinusoidal blood flow leading to sinusoidal 
dilatation and filtration of interstitial fluid. Non-inflammatory centrilobular cell 
necrosis of liver is found in nearly 70% of cases and reperfusion injury may 
lead to hepatocyte damage. Progressive fibrosis, nodular regenerative 
hyperplasia and cirrhosis develop during the course of disease. The acute form 
presents with jaundice, hepatomegaly, and upper abdominal pain with elevated 
liver enzymes. Portal hypertension and ascites are usually seen in chronic form. 
Liver biopsy shows congestion, liver cell loss and fibrosis predominantly in the 
centrilobular area. It is diagnosed by doppler ultrasonography showing ״spider 
web״ appearance of collateral hepatic venous circulation.18 Milder forms may be 
treated with surgical shunts and liver transplantation is the treatment of choice 
for patients with fulminant liver failure, failure of shunts or progression to 
cirrhosis.
19
 
5) METABOLIC DISORDERS OF LIVER:
20
 
 (a)Wilsons Disease (WD): 
           It is also known as ‘Hepato-lenticular degeneration’, is an autosomal 
recessive disease caused by mutation of the WD gene (on the long arm of 
chromosome 13). It causes an abnormal copper deposition in multiple organs 
including liver, brain, kidney and cornea. Clinical features are usually  
asymptomatic leading to chronic hepatitis, cirrhosis and fulminant hepatic 
failure. Neurological symptoms like dysarthria, dysphagia, apraxia and tremor 
predominantly seen in adults. The diagnosis is by the presence of Kayser-
Fleischer ring around the cornea, low serum ceruloplasmin level, increased 
urinary excretion of copper and elevated liver copper on biopsy. Chelation 
therapy with d- penicillamine, trientine, or ammonium tetrathiomolybdate has 
been shown to be effective in preventing progression of  Wilson’s disease. 
When medical treatment fails or patients present with fulminant failure, liver 
transplantation is the treatment of choice. 
(b) Hereditary Haemochromatosis: 
          It is an autosomal recessive disorder characterised by deposition of iron in 
tissues and organs. It is caused by homozygous C282Y mutation of the HFE 
gene, located on chromosome 6 and it is assosciated with changes in hepcidin 
which is the key regulator of iron homeostasis. Infants present acutely with liver 
failure in the perinatal period and demonstrate massively elevated ferritin levels, 
elevated iron saturation (98%), hyperbilirubinemia, hypoalbuminemia, 
hypoglycemia, and coagulopathy. Treatment of choice is phlebotomy with 
concomitant follow up of haematocrit. Liver transplantation is indicated for end 
stage liver disease. 
(c) α1-antitrypsin deficiency: 
          It is an autosomal recessive disease due to defective production of α1 
antitrypsin leading to decreased activity of  α-1 antitrypsin in the blood and 
lungs. Severe deficiency causes, chronic obstructive pulmonary disease or 
panacinar emphysema and liver injury in adults. In children, it may present as 
neonatal jaundice, hepatomegaly or acute liver failure. Diagnosis is by 
measurement of α1 antitrypsin in serum and liver biopsy (periodic acid Schiff 
positive after diastase digestion). Treatment is parenteral therapy using a plasma 
preparation of α1 antitrypsin with α1 antitrypsin < 11µmol/L and COPD. Liver 
transplantation is the treatment of choice in children and adults for end stage 
liver disease. 
(d) Cystic Fibrosis (CF): 
             It is a multisystem disease caused by mutation in the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene. The lack of CFTR alters 
ductular chloride secretion which causes viscous biliary secretions with 
subsequent biliary obstruction that leads to focal biliary fibrosis and ultimately 
cirrhosis. Depending on the report, 20%-50% of CF patients develop liver 
disease, which ranges from asymptomatic derangement of liver function tests to 
focal biliary fibrosis to cirrhosis with portal hypertension and chronic liver 
failure. Treatment with ursodeoxycholic acid (UCDA) has demonstrated 
improved bile flow and aminotransferases but does not stop the progression of 
fibrosis. Liver transplantation is indicated for end stage liver disease.  
(e) Tyrosinemia: 
                TT 1 is an autosomal recessive disorder due to a defect in fumaryl 
acetoacetate hydrolase enzyme in the tyrosine catabolism pathway, which 
results in accumulation of metabolites such as fumaryl acetoacetate and malelyl 
acetoacetate. It causes apoptosis of hepatocytes and renal tubular epithelial 
cells. Clinical features include acute liver failure, renal tubular dysfunction, 
chronic liver disease and hepatocellular carcinoma. Fumaryl acetoacetate and 
maleyl acetoacetate are alkylating agents that cause damage to DNA, which 
results in a predisposition to hepatocellular carcinoma. Treatment with 
Cyclohexendiome blocks tyrosine degradation and preventing formation of the 
alkylating metabolites. Liver transplantation is indicated for failure of medical 
treatment.  
6) Hepatocellular Carcinoma (HCC): 
            Hepatocellular carcinoma (HCC) is the sixth most common malignancy 
and is the leading cause of mortality in patients with cirrhosis. Cirrhosis is the 
most important risk factor for developing HCC in 80% to 90% of individuals 
and the annual incidence is 1% to 6 %. It occurs in chronic inflammatory 
condition of liver and is most closely linked to chronic viral hepatitis infection 
(hepatitis B or C) or exposure to toxins such as alcohol or aflatoxin. Certain 
metabolic diseases such as hemochromatosis and alpha 1-antitrypsin deficiency 
and non-alcoholic steato-hepatitis (NASH) markedly increase the risk of 
developing HCC.
21
 The clinical features are jaundice, abdominal distension, 
loss of appetite, weight loss, abdominal pain, nausea, vomiting, and malaise. 
The diagnosis is by liver biopsy,  blood levels of α- fetoprotein (AFP), 
Ultrasound, CT scan and MRI. On CT and MRI, it has three distinct patterns of 
growth, a single large tumour or multiple tumours or a poorly defined tumour 
with an infiltrative growth pattern. The most common sites of metastasis are the 
lung, abdominal lymph nodes and bone. Radio frequency ablation (RFA) is 
suitable for small tumours (< 5 cm). Liver transplantation is indicated for 
patients who are not eligible for resection, especially those within Milano 
criteria (solitary tumour ≤ 5 cm and up to three nodules ≤ 3 cm).22 
7) Cholangiocarcinoma: (CCA) 
           It is a primary neoplasm of the biliary system that arise from malignant 
transformation of cholangiocytes, the epithelial cells that line the biliary tree. 
The risk factors are chronic biliary inflammation, cholestasis, primary 
sclerosing cholangitis, choledochal cyst, caroli’s disease and chronic parasitic 
infection with liverfluke, Clonorchis sinensis. Morethan 90% of them are 
adenocarcinoma. The clinical features are obstructive jaundice, pruritus, 
malaise, abdominal pain, weight loss and loss of appetite. Laboratory tests 
demonstrate increased total and direct bilirubin, alkaline phosphatase (ALP) and 
gamma glutamyl transferase (GGT). Ulrasonography shows dilatation of 
intrahepatic bileducts and the presence of intrahepatic metastasis. Endoscopic 
retrograde cholangio pancreatography (ERCP), shows the biliary strictures and 
allows brush cytology and biopsy of the bile ducts. CT scan (Computerised 
tomography) and MRI (Magnetic Resonance Imaging) help in the evaluation of 
resectability and CA 19-9 is elevated in most cases. Surgical resection and 
neoadjuvant chemotherapy with liver transplantation is the treatment of choice 
in stage I and II. In patients with advanced disease, palliative chemotherapy 
with or without radiotherapy is the treatment of choice.
20
 
 
 
 MELD SCORE (MODEL FOR END – STAGE LIVER DISEASE):23 
          Model for End – Stage Liver Disease or MELD is a scoring system for 
assessing the severity of chronic liver disease and prioritizing for of Liver 
transplantation. It was initially used to predict the mortality of trans-jugular 
intrahepatic porto-systemic shunt (TIPS) surgery.  
              This score is now used by the United Network for Organ Sharing 
(UNOS) and Euro-transplant for prioritizing of liver transplants. It uses the 
patients value of 
1) Serum bilirubin, 
2) Serum creatinine, 
3) International normalised ratio (INR) for prothrombin time. 
         MELD = 3.78x log e [serum bilirubin (mg/dl)] + 11.2xlog e [INR] + 
                        9.57xlog e [serum creatinine (mg/dl)] + 6.43 
           MELD scores are reported as whole numbers, so the result of the above 
equation is rounded. Patient with decompensated liver disease and cirrhosis 
with Child pugh B/C or MELD score ≥24 are considered for liver 
transplantation.
24
 
 
 
Immunology of Transplantation: 
           Compared with other solid organ transplants, liver allografts have long 
been considered to be immunologically privileged manifested by an absence of 
hyper-acute rejection and a low incidence of graft loss due to chronic rejection. 
The hepatocytes have the potential to regenerate after tissue injury. However, 
acute liver rejection occurs in approximately 50% to 75% of liver transplant 
recipients and it is readily reversed with immunosuppressive drugs. 
Immunological Basis of Allograft Rejection: 
              In liver transplantation, grafts originate mainly from different members 
of the human species. The process of rejection is very complicated and has been 
shown to be caused by transplantation antigens including major 
histocompatibility antigens, minor histocompatibility antigens and other 
alloantigens. The major histocompatibility complex (MHC), encodes the 
dominant transplantation antigens and were shown to be similar to human 
leucocyte antigens (HLA) and are responsible for the self-restriction of 
immunological responses to conventional antigens.
25
 
Classification and Effector mechanisms of Allograft Rejection: 
           Allograft rejection mainly involves host-versus-graft reaction in liver 
transplantation, which is the rejection of the transplant by the recipient's body. 
The recipient's lymphocyte mediated reactions to allogeneic cells, leading to 
damage or destruction of the graft cells. The graft rejection has been divided 
into three groups namely hyper-acute rejection, acute rejection and chronic 
rejection.  
Type of rejection Time taken           Cause 
Hyper-acute 
 
        Minutes-hours 
 
 Pre-existing anti-donor antibodies & 
complement activation. 
Acute         Weeks - months Primary activation of T cells 
Chronic Months – years 
 
 
Causes unclear: antibodies, slow 
cellular reactions, immune 
complexes, recurrence of disease. 
 
Hyper-acute Rejection: 
          It often occurs within minutes to hours, after the host blood vessels are 
anastomosed to graft vessels. The rejection is mediated by preformed antibodies 
specific to the graft antigens (including ABO blood type antigens and HLA 
antigens) that can activate the complement of the host leading to damage to the 
endothelial cells. Studies have reported that the process is often accompanied 
with platelets activation and results in thrombotic occlusion of the graft 
vasculature causing ischemia, denaturation and necrosis. This rejection is 
relatively rare in liver transplantation.
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Acute Rejection: 
         It occurs within days and up to three months after transplantation (80-90% 
of cases occur within one month). The rejection occurs due to donor HLA 
interaction with the host T cells, creating a cascade of immune responses. The 
mechanisms involve humoral and/or cellular mechanisms. Antibodies can injure 
the graft by activating complement and mononuclear cells with Fc receptors that 
recognise allo-antigens on the endothelial cells resulting in vasculitis. Cytotoxic 
T cells (CD8+) will recognise allo-antigens on antigen presenting cells (APC) 
by direct presentation on the donor tissue and endothelial cells, which promotes 
the apoptosis of transplanted tissue. It has been shown that CD8+ cells alone are 
sufficient for the mediation of acute allograft rejection, but with the help of 
CD4+ cytokines secretion such as IL-2, the expression and clonal expansion of 
cytotoxic attack molecules will be upregulated.
26
 The Fas/Fas ligand (FasL) 
pathway is another pathway which cause activation of CD8+ cells. The 
pathological features of acute rejection are acute vasculitis and parenchymal cell 
necrosis, along with the infiltration of lymphocytes and macrophages. The acute 
rejection that occurs after liver transplantation is rare. 
Chronic Rejection: 
          It occurs, months or years after acute rejection reactions have subsided. It 
is an indolent but progressive form of allograft injury that is usually irreversible 
and results in allograft failure. It affects only 4-8% of patients after 5 years of 
liver transplant. Chronic rejection is potentially reversible in liver allograft 
compared to other solid organ transplants and has been mainly attributed to its 
unique immunological privilege and its regenerative capacity. Liver biopsy 
shows decreased number of bile ducts, known as "vanishing bile duct 
syndrome".
27
 Chronic rejection is characterised by vasculopathy, fibrosis and a 
progressive loss of organ function. The persistent viral infections which induce 
cellular immune responses may synergise with donor-specific alloreactive T 
cells within the allograft. It may also reflect chronic ischemia secondary to the 
injury of blood vessels by antibody or cell-mediated mechanisms. 
Prevention and Treatment of Allograft Rejection: 
        Treatment of allograft rejection refers to immunosuppressive therapy, 
involving an immunosuppressive drugs selection and regimen. 
 IMMUNOSUPPRESSANTS:
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          Survival of both patient and graft following Liver transplantation is made 
possible through immunosuppression, using immunosuppressive drugs. Studies 
have shown that standard therapy with steroids and calcineurin inhibitors are 
highly effective in maintaining immunosuppression.  
1) Corticosteroids: 
        Corticosteroids have been used for induction of immunosuppression since 
the first successful cases of solid organ transplantation. Almost all patients 
receive corticosteroids following transplantation. It has potent anti-
inflammatory and immunosuppressant action. They cause redistribution of 
lymphocytes, causing rapid decrease in peripheral blood lymphocyte count. 
They bind to receptors inside cells and regulate the transcription of numerous 
other genes. Additionally, they inhibit activation of NF-kB, which increase 
apoptosis of activated cells. The pro-inflammatory cytokines such as IL-1, IL-2 
and IL-6 are downregulated. T cells activation and proliferation are inhibited. 
Corticosteroid are administered in high doses, as intravenous injections during  
the first few days after transplantation in combination with at least one 
immunosuppressant agent. The typical dosage is 500mg or 1000 mg of 
methylprednisolone. They are rapidly tapered over the first week to relatively 
low doses of 10 to 20 mg daily (oral prednisolone) and are usually maintained 
in immunosuppression regimen for atleast, the first 3 to 6 months after 
transplant. The use of steroid is associated with many adverse effects like 
hypertension, cushingoid appearance, weight gain, dyslipidemia, osteoporosis,  
diabetes, cataracts, and increased risk of infections. There is also concern that 
higher doses of steroids, increase the risk of disease recurrence in LT patients 
with chronic viral hepatitis and the risk of organ rejection may increase 
following early corticosteroid dose reduction or withdrawal. 
2) Cyclosporine A: 
          It is a cyclic polypeptide derived from the fungus, Beauvaria nivea. It acts 
by binding to cyclophilin, a cytoplasmic protein receptor and the complex binds 
to calcineurin and inactivate it. This complex inhibit the calcium stimulated 
dephosphorylation of the cytoplasmic component of nuclear factor activated T 
cells (NFAT) and inhibit interleukin 2 (IL-2) production. It is the most effective 
drug for prevention and treatment of graft rejection by suppressing cell 
mediated immunity. It is metabolised in liver by CYP3A and its metabolites are 
excreted through bile into the faeces, with some (6%) excretion in urine. The 
plasma t½ is biphasic 4-6hrs and 12-18hrs. It is given according to blood levels 
and renal function. The drug is started at 1-2 mg/kg/day in two divided doses 
and increased as tolerated, but the maintenance dosage ranges from 1-10 
mg/kg/day. Generally, the 2-hour post dose level is measured and is believed to 
reflect immunosuppression. The major adverse effect is nephrotoxicity, due to 
intra-renal vasoconstriction and occurs in 40-70% of patients, manifested by 
acute elevations in blood urea nitrogen and creatinine level which is usually 
reversible with reductions in dosage. Other adverse effects include 
hyperkalemia, hypertension, venous thrombosis, tremor, headache, gout, 
gingival hyperplasia, seizures and hyperlipidemia.  
3) Tacrolimus (FK506): 
          It is a macrolide antibiotic produced by Streptomyces tsukubaensis. Like 
cyclosporine, tacrolimus also inhibits calcineurin that causes decreased IL-2 
production and thereby inhibit T-cell activation and proliferation. The drug acts 
by binding to intracellular protein, FK 506 binding protein-12 (FKBP-12) and is 
100 times more potent than cyclosporine in inhibiting IL-2 synthesis. A 
complex of tacrolimus-FKBP-12, calmodulin and calcineurin then forms and 
inhibit calcineurin phosphatase activity which prevents dephosphorylation and 
nuclear translocation of NFAT. This, inhibit T- cell activation and proliferation. 
It is metabolized in the liver by cytochrome P-450 system. The plasma    is 12 
hours. The usual oral dosage is 0.1-0.15 mg/kg/day and was adjusted according 
to liver function and tacrolimus trough concentration. It requires blood level 
monitoring for dose adjustment and the ideal serum trough level is 5-10 ng/ml. 
The adverse effects of tacrolimus are diabetes, neurotoxicity, gastrointestinal 
disturbances, hypertension and hyperkalemia.  
4) Sirolimus: 
         It is structurally similar to tacrolimus was called as ‘Rapamycin’ earlier. It 
binds to FKBP (FK binding protein) as tacrolimus and inhibit a protein kinase 
called ‘mammalian target of rapamycin’ (mTOR). The mTOR is an important 
link in the cascade of signalling pathways that leads to proliferation and 
differentiation of  T- cells activated by IL-2 and other cytokines. It is 
metabolized by CYP3A4 and excreted through bile in faeces. The plasma t½ is 
60 hours. It may be combined corticosteroids and other immunosuppressants. 
The main adverse effects are bone marrow suppression (thrombocytopenia, 
anemia, leukopenia), hyperlipidemia, poor wound healing, mouth ulcer, 
hypokalemia, proteinuria and gastrointestinal effects. 
 
5) Mycophenolate mofetil (MMF): 
             It is an antibiotic isolated from Penicillium species, that has 
immunosuppressant properties. It is a prodrug of mycophenolic acid which 
selectively inhibits inosine monophosphate dehydrogenase, an enzyme essential 
for denovo synthesis of guanosine nucleotides in the T and B cell. It is a potent 
inhibitor of B-cell and T-cell proliferation, antibody production and cell 
mediated immunity. It is used in combination with corticosteroids and 
cyclosporine / tacrolimus. It is absorbed orally and metabolized in the liver to its 
active form, mycophenolic acid. It is slowly glucuronidated in the liver to an 
inactive form, phenolic glucoronide and is then excreted in urine. The plasma 
t½ is 16 hours. The oral dosage is 2-4 g/day, orally or intravenously and blood 
level monitoring is not required. The major adverse effects are vomiting, 
diarrhoea, leucopenia and predisposition to CMV (Cytomegalo virus) infection. 
6) Monoclonal Antibodies: 
 (a) Muromonab: 
          It is an anti-CD3 monoclonal antibody, primarily used in liver 
transplantation for steroid resistant acute rejection. It binds to CD3, a 
monomeric component of T-cell receptor complex involved in antigen 
recognition, cell signalling and proliferation. It is then followed by depletion 
and extravasation of majority of T cells from the blood and peripheral lymphoid 
organs. It also reduces the production of cytokines like IL-2 and thereby reduce 
T cell activation and proliferation. The recommended dose is 5mg/day for adults 
in a single intravenous bolus (<1 min) for 10 – 14 days. The major side effect is 
cytokine release syndrome which begins 30 minutes after infusion antibody 
infusion and is assosciated with increased release of cytokines like TNF α, IL-2, 
IL-6 and IFN ϒ. Common side effects are high fever, chills, rigor, headache, 
tremor, nausea, vomiting, diarrhoea, abdominal pain, myalgia and arthralgia. 
Corticosteroids administration before the injection of muromonab, prevents the 
release of cytokines and reduce the first dose reactions is considered as a 
standard procedure. 
(b) Polyclonal Antibodies: 
            It includes anti-thymocyte (ATG) and anti-lymphocyte globulins (ALG). 
They are prepared by inoculating rabbits or horses with human lymphocytes or 
thymocytes. Their mechanism of action is rapid lymphocyte depletion due to 
complement mediated cell lysis and uptake of opsonized T cells by reticulo- 
endothelial cells. Lymphocyte depletion, plays a major role in preparing the 
recipient’s immune system to adapt and recognize the transplanted organ as self 
and prevent destruction of the allograft. At present, anti-lymphocyte antibodies 
are used to treat steroid-resistant acute rejection extensively and are successful 
in 70%-96% of patients. The main side effect is “first-dose reaction” and febrile 
episode affecting 80% of patients which can often be reduced by pre-medication 
with antipyretics, antihistamines and intravenous steroids. Other adverse effects 
include thrombocytopenia, anaemia, CMV infection, PTLD, pruritic skin 
rashes, serum sickness and anaphylaxis. 
 Post-transplant Complications: 
            The most common complications in the liver transplant recipients are the 
following: 
   1) Acute graft rejection 
   2) Vascular thrombosis 
   3) Biliary leak or stricture 
   4) Infection 
   5) Malignancy 
   6) Adverse effects of Immunosuppresant drugs. 
1) Acute graft Rejection: 
         Acute rejection occurs in 20-70% of cases, most often at 7-14 days after 
transplant, and results in graft dysfunction. It is clinically manifested as low 
grade fever, malaise, jaundice and abdominal tenderness. It may be subclinical, 
with laboratory abnormalities as the only sign. Bilirubin and alkaline 
phosphatase levels rise initially, followed by elevations of alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST). It is most 
commonly treated with high-dose steroids ( methylprednisolone 1 g for 3 days)  
followed by a rapid taper over 5-7 days. Alternative therapies include 
monoclonal antibody therapy with Muromonab or polyclonal antibody 
(Antithymocyte globulin). 
2) Chronic graft Rejection: 
            It occurs months or years after transplantation and is usually irreversible. 
It occurs in 5% of patients and is the major cause of late graft failure. It is 
diagnosed by of liver biopsy, manifested by gradual obliteration of small bile 
ducts. The laboratory results show persistently elevated serum alkaline 
phosphatase and bilirubin levels, suggesting a cholestatic liver injury pattern.  
This may manifest clinically as jaundice and /or pruritus. Tacrolimus has been 
used to treat refractory cellular rejection and early chronic rejection. When 
patients fail to repond to tacrolimus rescue therapy, MMF rescue therapy or 
antiboby (monoclonal or polyclonal) therapy is given. When the above 
measures fail, retransplantation is done.  
3) Infections after Liver Transplantation: 
          Infections are the major cause of morbidity and mortality after liver 
transplantation despite of advances in surgical technique, post-transplant care, 
hospital environments, immunosuppression and infection prevention. 
1) Bacterial Infections: 
            They are the most common causes of infection after liver transplantation 
and the highest incidence occurs during the first month after transplantation and 
these infections involve the surgical site, the abdominal cavity, bloodstream, 
urinary system, and the respiratory tract, predominantly.  
 
              Most of the infections are caused by nosocomial organisms, the 
patient’s normal flora and can also be transmitted from the donor. During the 
second to sixth months after LT, opportunistic infections may occur, depending 
on patients’ risk factors and the intensity of immunosuppression. At 6 months 
after LT, infections are related to environmental exposure, late biliary 
complications, graft function and combined viral hepatitis. At 12 months after 
LT, urinary tract infections, intra-abdominal infections and pneumonia are the 
major types of infection in solid organ transplant recipients. Shifts in 
nosocomial pathogens, increasing antibiotic resistance, potent 
immunosuppression, improved diagnostic methods, grafts from marginal donors 
and broader epidemiologic exposure, influence the risk and outcomes of 
bacterial infections.
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(A)Surgical Site Infections: 
             It is one of the most common bacterial infections found to manifest 
itself early after liver transplantation. It is most often manifested as erythema, 
induration, tenderness and drainage at the surgical site. Leukocytosis and fever 
may occur in some cases. It is more common in liver recipients who require a 
large number of blood transfusions and prolonged duration of the 
surgery.
1
Currently, the overall incidence of SSI ranges from 18% to 37%. They 
are most commonly caused by gram positive cocci (Staphylococcus aureus and 
enterococcus), gram negative pathogens (like Enterobacteriaceae, Pseudomonas 
aeruginosa, and Acinetobacter baumannii), anaerobe and fungi. Treatment 
consists of surgical debridement and pathogen directed antimicrobial therapy.
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(B)Intra-abdominal Infections: 
          It accounts for 27%-47% of early bacterial infections after liver 
transplantation. Intra-abdominal abscesses, peritonitis, and cholangitis are 
commonly present during the first few weeks after liver transplant as fever, 
leukocytosis and abdominal pain. They may be asymptomatic clinically which 
are manifested as elevated liver enzymes are common. The pathogens are most 
often polymicrobial and at present, often include multi-drug resistant isolates.1 
Some of the important bacteria causing intra-abdominal infections are 
enterococci, including VRE, Staphylococcus aureus including MRSA, Candida 
species, and Gramnegative bacilli such as Pseudomonas species, Klebsiella 
species, Acinetobacter species and Enterobacter species.
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 They are associated 
with increased mortality, graft loss and re-transplantation. When suspected 
clinically, CT scan or Ultrasound is done to diagnose the presence of fluid 
collections. Treatment consists of percutaneous or open surgical drainage 
combined with antimicrobial therapy. 
(C)Bloodstream Infections: 
           It may occur at any time after transplantation and the majority occurs 
during the first post-operative month. Risk factors include intra-abdominal 
infection, prolonged use of indwelling vascular catheters, the need for 
reoperation and acute allograft rejection. Clinical manifestations most often 
include fever and rigors, accompanied by leucocytosis and organ-specific or 
localizing symptoms such as erythema and drainage at vascular catheter sites, 
cough and dyspnoea (pneumonia), dysuria and suprapubic and flank pain 
(urosepsis).
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 The most common source of bloodstream infections are due to 
enterococcus, viridans streptococcus, gram-negative bacilli or may be poly-
microbial.
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 Now, there is an increasing prevalence of multi-drug resistant 
bacteria such as methicillin resistant staphylococcus aureus, which may cause 
50% of bloodstream infections in some centres. Transplant candidates who are 
carriers of MRSA have a higher risk of bloodstream infection and may be 
decolonized prior to transplantation.
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 Escherichia coli is the most common 
organism causing bloodstream infection after liver transplantation, followed by 
Klebsiella pneumoniae and Pseudomonas aeruginosa.
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 There is increasing 
resistance among these gram negative pathogens and the prevalence of extended 
spectrum β lactamases (ESBL) producing Gram-negative bacilli is 13%  in 
some centres. Treatment consists of elimination of the predisposing factor and 
pathogen directed antimicrobial therapy. For persistent bloodstream infections, 
endocarditis should be evaluated by means of a trans- esophageal 
echocardiogram.  
(D)Pneumonia:   
            Because of the prolonged surgery, frequent use of mechanical 
ventilation, immunosuppression, massive transfusions, fluid overload and 
underlying malnutrition, liver transplant recipients are more prone to respiratory 
tract infections. It occurs in 11%-28% of liver transplant recipients with  
nosocomial pneumonia occurring in 50%-75% and community-acquired 
pneumonia in 25%-50%.
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 Currently, bacterial pneumonia is the most common 
infection followed by fungal pneumonia, during the first month after liver 
transplantation.
37
 Treatment consists of pathogen-specific antimicrobial therapy 
with or without reduction of immunosuppressive agents. After, One month of 
transplantation, the bacterial pneumonia occur less common. At 6 months after 
LT, in patients with good graft function and immunologically stable, the 
bacterial pneumonia is similar to that of non-LT patients.
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(E)Urinary Tract Infection:(UTI) 
             It was the most common primary source of bacterial infection, for 6 
months after solid organ transplantation. The risk factors are age, female sex, 
diabetes and long term urinary indwelling catheter. The most common 
pathogens are Escherichia coli, Enterococcus species, Klebsiella species, 
Staphylococcus aureus and Enterobacter species.
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 Urinary tract infections are 
the common sources of antibiotic resistant bacterias such as ESBL producing 
Enterobacteriaceae, vancomycin-resistant enterococci (VRE) and methicillin 
resistant staphylococci (MRSA).
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2) Viral Infections: 
          Liver transplant recipients are unique among other transplant recipients 
because they are commonly chronically infected with hepatitis B or C viruses. 
Among the opportunistic viral pathogens, the most commonly occurring are 
members of the herpes virus group, of which cytomegalovirus is the most 
important infection.  
 
 
(A)Cytomegalovirus Infection (CMV): 
               The seroprevalence rate of CMV infection in humans ranges from 
45% to 100%. The high infection rate in transplant recipients is due to its ability 
to establish latency inside the cells. The immunocompetent hosts are usually 
asymptomatic and the liver recipients often present with severe clinical 
presentation. The most common symptoms are fever and bone marrow 
suppression (CMV syndrome). The severe infection present as gastritis or colitis 
and manifests itself as abdominal pain and diarrhoea. Endoscopic findings, 
consists of mild hyperemia, mucosal erosions and ulcerations or even normal 
mucosa. The second clinical symptom is CMV hepatitis, which usually presents 
with abnormal liver function tests and can be confirmed by means of biopsy, 
where inclusion bodies with clusters of polymorphonuclear cells are seen.
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Other system such as the central nervous system and the respiratory system may 
be infected and presents as headache, delirium, changes in mental function, 
cough and dyspnoea respectively. Currently, biologic markers such as CMV 
pp65 antigens or CMV DNA by polymerase chain reaction are used as the 
earliest indicators of infection.
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 Treatment of CMV disease is with 
intravenous ganciclovir (5 mg/kg every 12 hours) or oral valganciclovir (900 
mg orally twice daily), combined with reduction in immunosuppression. Mild to 
moderate cases are treated with oral valganciclovir. For severe cases, along with 
intravenous ganciclovir, hyperimmunoglobulin is used as an adjunct treatment. 
The efficacy of treatment is guided by serial weekly monitoring of viral load or 
antigenemia levels.
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(B)Epstein Barr Virus Infection (EBV): 
             It can present in a variety of ways after liver transplantation. Acute 
infection is manifested as fever, malaise with leukopenia, atypical 
lymphocytosis or thrombocytopenia. Primary EBV infections, occurs 
predominately in children and it is estimated that 90% of adults are EBV 
seropositive due to previous subclinical infection. In adults post liver transplant 
with active EBV infection, reactivation is presumed to be the predominant 
pathophysiologic process.
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 Acute illness is usually self-limited. EBV infection 
can lead to post transplant lymphoproliferative disorder (PTLD) in the liver 
recipient. EBV associated PTLD is an uncommon but is a serious complication 
of liver transplantation with an incidence in adults of less than 3%.
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 Risk 
factors include, primary EBV infection, presence of CMV disease and increased 
immunosuppression. The EBV assosciated PTLD include lymphadenopathy, 
pancytopenias, fever, and disturbances of gastrointestinal tract, lungs, spleen, 
and central nervous system. Radiographic studies can identify the involvement 
of pulmonary or intra-abdominal sites. The detection of EBV viremia with 
nucleic acid testing is not diagnostic of EBV associated PTLD. The treatment is 
a reduction of immunosuppression.
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 When there is no clinical response within 
2–4 weeks, anti-CD20 monoclonal antibodies (rituximab) may be required. 
3) Fungal Infections: 
         Among the various fungal infections after liver transplant, the most 
common are the Candida species followed by Aspergillus species. 
(A) Candida Infection:  
            Candidiasis is the most common fungal infection after liver 
transplantation and is the leading cause of invasive fungal infection. The 
Superficial and invasive candidiasis occurs often during the first 1-3 months 
after liver transplantation. Candida albicans is the most common species and 
now, the non-albicans candida species are being reported from blood cultures 
more frequently. The most common symptom is mucosal candidiasis but the 
more fatal illness is invasive candidiasis. Invasive candidiasis can be primary or 
secondary to infected catheters or surgical wounds.
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 Risk factors for invasive 
candidiasis, include prolonged surgery, surgical procedure, increased blood 
transfusions, previous Candida species colonization and renal failure after liver 
transplantation.  
           The American Society of Transplantation recommends antifungal 
prophylaxis against Candida to high-risk liver recipients
50,52
 and the duration of 
prophylaxis is for 4  weeks in many centres. Clinical studies have shown that 
fluconazole, itraconazole or amphotericin B prophylaxis markedly reduced the 
incidence of invasive candidiasis in liver recipients. Treatment of invasive 
candidiasis after liver transplantation, is a combination of antifungal therapy 
and reduction of immunosuppression.  
(B) Aspergillus Infection: 
         After Candida species, the second most common fungal infection is 
invasive aspergillosis occurring in 1% - 9.2% in liver recipients. The most 
important risk factors are retransplantation, renal failure, prolonged stay in 
intensive care unit, CMV disease and fulminant hepatic failure.
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 Aspergillus 
fumigatus is the most common species whereas Aspergillus niger, Aspergillus 
flavus and Aspergillus tereus are less common.
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 In a recent study of the clinical 
features of invasive aspergillosis from 23 United states transplant centres, the 
most common clinical presentation (90%) was lung infection and occur during 
the first year after transplant.
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 The liver recipients with invasive fungal 
infection had the highest mortality reported, because of the severity of the 
illness and the underlying immune-compromised status. The possibility of 
invasive aspergillosis should be suspected in the presence of risk factors and 
clinical findings, and should be confirmed by any one of the following, (1) 
lower respiratory tract infection symptoms and CT images showing well 
circumscribed lesions with or without the halo sign, air-crescent sign or cavity, 
(2) central nervous system infection with focal lesions on imaging or (3) 
recovery by culture of the mold. The American Society of Transplantation, 
recommends the use of a amphotericin B (3-5 mg/kg per day) or an 
echinocandin for high risk patients and the duration of  prophylaxis is for 4 
weeks after liver transplantation.
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 The current guideline recommends, 
voriconazole as the first-line of choice for the treatment of invasive 
aspergillosis.
54
 
Evaluation Of Infections after Liver Transplantation:
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        Infection in the early post-transplant period (<1 month) is most commonly 
bacterial and are primarily nosocomial such as enterococci, staphylococci, 
gram-negative aerobes, anaerobes or candida species. They are most commonly 
intra-abdominal (cholangitis, liver, and other abdominal abscesses) and are 
observed during the post-transplant hospitalization. Infected transplant patients 
may present with fever, abdominal pain or jaundice or they may be possibly 
asymptomatic because of immunosuppression. A complete blood investigation, 
liver function tests, renal function test, coagulation profile, urine analysis were 
done. Symptomatic investigations are done for culture. Further investigations 
may include radiological investigations, abdominal ultrasonography, 
computerised tomography (CT), endoscopic retrograde cholangio- 
pancreatography (ERCP) and liver biopsy. 
            During 1-6months, the infections are most commonly due to viruses or 
opportunistic organisms. After 6 months of transplant, the risk of infection is 
similar to that of the general population. The most common causes of infection 
in the outpatient setting are the typical community-acquired pathogens which 
are treated with the antimicrobials, typically prescribed for non-
immunosuppressed patients (with caution regarding drug interactions). 
Incidence declines after 6-12 months, if the recipient is on a stable 
immunosuppressant regimen. 
Symptoms and Signs of Infection: 
         The classic signs and symptoms of infection are often absent because of 
immunosuppression. Fever is the most common symptom caused by infection 
or may also be due to rejection or drugs. Fever may be low-grade or absent and 
leukocytosis may not be present. Pain at sites of infection may be minimal 
because of the patient's decreased ability to mount an inflammatory response. 
Infection may progress more rapidly than in the normal patient and may be 
more difficult to eradicate. A complete blood investigation, radiological 
investigations, abdominal ultrasonography and liver biopsy were done to rule 
out infections. 
Folllow Up: 
       The patient was reviewed in the surgical gastroenterology department every 
month in OPD (Outpatient department).  Since most liver transplant patients are 
immunosuppressed and come to medical attention as a last resort, every 
complaint should be taken seriously and the patients infected require admission 
because they will need a decrease in their immunosuppressants and are at risk of 
rejection. Fever of unknown origin or suspicion of rejection should be 
considered for admission for further evaluation. Symptomatic investigations and 
complete blood investigations are done. If bacterial infection was suspected, 
cultures are obtained and antibiotics initiated, based on culture and sensitivity as 
in the non-immunocompromised patient. Broad-spectrum antibiotics are given, 
if the source is unknown because these patients are on long-term corticosteroids 
and should be prescribed only after reviewing the information of drug 
interactions.  
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS: 
STUDY PLACE: 
1) Department of Microbiology, Government Stanley Medical College,  
Chennai. 
2) Department of Surgical Gastroenterology, Government Stanley Medical  
College, Chennai. 
STUDY DESIGN:  
      Prospective study. 
SAMPLE SIZE: 
       15 in numbers. 
STUDY PERIOD: 
     October 2016 – July 2017. 
ETHICAL CONSIDERATION: 
         Ethical and research clearance was obtained from the Ethical committee, 
Stanley medical college. Permission to conduct the study was sought from the 
respective hospital department authorities. An informed consent was obtained 
from the patient before enrolment into the study. 
 
STATISTICAL ANALYSIS: 
       The collected data were analysed with IBM.SPSS statistics software 23.0 
Version. To describe about the data, descriptive statistics, frequency analysis, 
percentage analysis were used for categorical variables and the mean & 
Standard deviation (S.D) were used for continuous variables. 
INCLUSION CRITERIA: 
       All patients undergoing liver transplant surgery at Institute of Surgical 
Gastroenterology in Govt. Stanley Medical College, during the study period. 
SAMPLE COLLECTION AND LABORATORY TESTING: 
DONOR:  
        Complete blood investigations, Throat swab c/s, Nasal swab c/s, Blood c/s 
& Urine c/s were done to rule out infections. 
RECIPIENT: 
       Throat swab c/s, Nasal swab c/s, Blood c/s & Urine c/s before surgery to 
rule out infections. Symptomatic investigations are done daily and biochemical 
tests include, Complete blood investigations, Liver function test, Renal function 
test, Coagulation profile, Serum pro-calcitonin, Tacrolimus or Cyclosporine 
assay. 
 
 SAMPLE COLLECTION:
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THROAT SWAB: 
       It was made sure that the patient was not treated with antibiotics, 8 hours 
before swabbing. In a good light from over the shoulder, the patient is instructed 
to tilt the head back and breathe deeply. The tongue is depressed using a tongue 
depressor to visualize the tonsillar fossae and posterior pharynx. The tonsillar 
area and the posterior pharyngeal wall are rubbed using a sterile cotton wool 
swab. Two swabs were taken, one for gram’s stain and other for culture. 
NASAL SWAB: 
       Nasal swabs are obtained under direct vision using over-the-shoulder 
illumination. With the thumb of one hand gently lift the tip of nose. Moisten the 
tip of sterile cotton swab with sterile water or saline and gently insert into one 
of the nares. Guide the swab backward and upward along the nasal septum until 
a distinct feel of resistance indicates that a posterior pharynx has been reached. 
URINE CULTURE: 
       After cleaning the external genitalia with soap and water, then rinse with 
water and a clean voided mid-stream urine is collected in a sterile wide mouthed 
container. In indwelling catheter (Foley’s catheter), disinfect the catheter 
collection port and aspirate 5 – 10 ml of urine with sterile needle and syringe 
and add it into sterile screw cap container.  
BLOOD CULTURE: 
      The blood should be collected before antimicrobial treatment has started.To 
increase the chances of isolating the pathogen, it is usually recommended that at 
least two specimens are collected at different times and cultured. Under strict 
aseptic precautions, about 5 – 10 ml of blood is collected using a sterile syringe 
and needle in a sterile screw capped liquid culture bottle containing 50ml 0f 
brain heart infusion broth. It is then incubated at 37ᵒ C for 1 week. When 
growth is suspected, sub-culturing is done on blood agar and macconkey agar 
and the organism was isolated. 
CENTRALVENOUS CATHETER TIP CULTURE: 
         Disinfect the skin before removal and the catheter tip is collected in a 
sterile screw cap container. It is cultured qualitatively by rolling the tip back and 
forth across the blood agar and macconkey agar with sterile forceps four times. 
BODY FLUIDS CULTURE: (Abdominal, peritoneal, bile, pleural and 
drainage fluid) 
        Disinfect the skin before aspiration and aspirate about 2 – 3ml using a 
sterile needle and syringe into a sterile test tube. 
PUS CULTURE: 
        Pus from an abscess is best collected at the time, it is incised and drained, 
or after it has ruptured naturally. Using a sterile technique, aspirate or collect 
from a drainage tube up to 5 ml of pus and transfer to a leak-proof sterile 
container.  
WOUND SWAB: 
           Using a sterile cotton-wool swab, sample is collected from the infected 
site. Immerse the swab in a container of Amies transport medium. Usually, 2 
swabs are collected, one for culture and the other for gram staining. 
SPUTUM CULTURE: 
          A sterile, dry, wide-necked, leak-proof container was given to a patient 
and requested to cough deeply to produce a sputum specimen. Sputum is best 
collected in the morning soon after the patient wakes and before any mouth-
wash is used. When pulmonary tuberculosis is suspected, up to three specimens 
may need to be examined to detect acid fast bacilli. 
BRONCHO ALVEOLAR LAVAGE: 
          Bronchial and alveolar washings (broncho-alveolar lavage), are collected 
using a bronchoscope. The specimen must contain alveolar exudate if cysts are 
to be found. 
 
 
ANTIBIOTIC SUSCEPTIBILITY TEST BY KIRBY BAUER’S DISC 
DIFFUSION METHOD: 
       The Muller Hinton agar is the standard agar based medium used for testing 
of most bacterial organisms. The appropriate concentrations of drug for each 
disk is determined by the United states, Food and Drug Administration (FDA). 
Before disk placement, the agar plate is inoculated using a swab that has been 
submerged in a bacterial suspension standardised to match the turbidity of 0.5 
Mcfarland turbidity standard equivalent to 1.5 x 10
8 
CFU/ml. The surface of the 
plate is swabbed in 3 directions to ensure even and complete distribution of the 
inoculum. Within 15 minutes of inoculation, the antimicrobial disks are placed 
and incubated at 37ᵒ C for 16 – 18 hrs. The incubation time may be increased 
beyond 16 hours for certain resistant organisms like methicillin resistant in 
staphylococcus aureus and vancomycin resistant in enterococci. After 
incubation, a dark background and reflected light are used to examine a disk 
diffusion plate. A ruler or caliper can be used to measure the diameter of zone 
of inhibition of each antimicrobial agent. Interpretive criteria for antimicrobial 
agent / organisms may be tested by disk diffusion are provided in the Clinical 
and Laboratory Standard Institute (CLSI- M2 series), “Performance Standard 
for Antimicrobial Disk Susceptibility Tests (M 100 supplements)”.  
 
 
E-TEST (Epsilometer Test): 
       It is a type of disc diffusion method used to detect the minimum inhibitory 
concentration of particular organisms against particular drug that is 
commercially in plastic strips. The one side of the strip contains antimicrobial 
agent concentration gradient and the other side contains a numerical scale that 
indicates the drug concentration. Muller Hinton plate was inoculated as for disk 
diffusion and the strips are placed on the inoculum lawn. Several strips may be 
placed radially on the same plate. After overnight incubation, the plate is 
examined and the number present at the point where the border of growth 
inhibition intersects the E- strip is taken as the minimum inhibitory 
concentration (MIC) of the drug. In this study, this test was done to detect the 
MIC of vancomycin against Methicillin resistant Staphylococcus aureus. 
Vancomycin with MIC ≤ 2mm is sensitive, 4 – 8 mm intermediate sensitive and 
≥ 8mm resistant according to CLSI M-100, S 26.  
COMPLETE BLOOD INVESTIGATIONS:
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         It includes, total white blood cell (WBC) count, differential count, red 
blood (RBC) cell count, platelet count, haemoglobin (Hb), packed cell volume 
(PCV), mean corpuscular volume (MCV), mean corpuscular haemoglobin 
(MCH), mean corpuscular haemoglobin concentration (MCHC) and blood 
sugar. 
URINE COMPLETE ANALYSIS: 
         It includes specific gravity, pH, colour, appearance, WBC esterase, 
protein, glucose, ketones, occult blood, bilirubin, urobilinogen and nitrite. 
SERUM ELECTROLYTES: 
            It includes serum sodium, potassium, chloride, calcium, magnesium and 
phosphorus. 
LIVER FUNCTION TEST: 
          It includes measurement of serum alanine transaminase (ALT), aspartate 
aminotransferase (AST), alkaline phosphatase (ALP), gama- glutamyl 
transferase (GGT), total protein, serum albumin, serum globulin, total bilirubin, 
direct and indirect bilirubin levels. 
RENAL FUNCTION TEST: 
        It includes measurement of blood urea nitrogen (BUN) and serum 
creatinine. 
COAGULATION PROFILE: 
        It includes prothrombin time (PT), international normalised ratio (INR), 
activated partial thromboplastin time (APTT) and serum fibrinogen. 
 
TACROLIMUS ASSAY: 
         It is a chemi-luminescent microparticles immunoassay (CMIA), used for 
the quantitative measurement of tacrolimus in human whole blood on the 
ARCHITECT i system. The ARCHITECT Tacrolimus assay is used as an aid in 
the management of liver allograft patients receiving tacrolimus therapy. The 
tacrolimus trough levels should be within the therapeutic range (5-10 ng/ml) 
because acute rejection and toxic side effects, are common at the lower and 
upper extremes of this range. 
CYCLOSPORINE LEVEL: 
          It is used to measure cyclosporine level in whole blood, to maintain 
adequate immunosuppression. It is a high performance liquid chromatography 
method. About 2ml of blood was collected in an EDTA (Ethylene diamine tetra- 
acetic acid) added tube immediately to the next dose. The therapeutic reference 
range for liver transplant patient is 150 – 200 µg/ml for 6 months after liver 
transplant and 100 – 150 µg/ml for > 6 months of transplantation. 
REAL-TIME PCR: 
       It is a variation of standard polymerase chain reaction (PCR) technique that 
is commonly used to quantify DNA or RNA in a sample. By measuring the 
amount of amplified product at each stage during the PCR cycle, quantification 
is possible. The nucleic acid must be extracted first from the clinical specimen 
as with conventional PCR. The denaturation of double stranded nucleic acid by 
heating at 94ᵒ C followed by primary annealing and extension are performed in 
one cycle. The sequence of the primers and probes were selected from the EBV- 
encoded RNA (EBER) gene for EBV. The forward and reverse primer 
sequences for EBV were 5´-AAACCTCAGGACCTACGCTGC-3´ and 5´-
AGACACCGTCCTCACCAC-3´ respectively. EBNA LP1 region (Nuclear 
Antigen Leader Protein), was selected for amplification and detection. The 
detection of specific amplification product indicates the presence of ENV DNA 
in the specimen. 
 FOLLOW UP INVESTIGATIONS: 
            After discharge from the hospital, the recipients need lifelong follow up. 
Initially patient was reviewed weekly for the first 1 month, then monthly for 6 
months and then every 3 months. If the patient had any symptoms after 
discharge was admitted immediately. Complete blood investigations, Liver 
function test, Renal function test and coagulation profile was done. The trough 
level of tacrolimus was also monitored. Culture was done depending on the 
symptoms and antibiotics were given based on antibiotic sensitivity report.    
 
 
 
                                OBSERVATION AND RESULTS 
             About 15 Liver transplant patients were followed during the study 
period, in the department of Surgical Gastroenterology, Stanley Medical 
College. Specimens taken include throat swab, nasal swab, blood culture, urine 
culture, wound swab, central venous tip culture, drainage fluid culture and 
blood for serological test. All the specimens were processed in the department 
of Microbiology in our institute and the results obtained were analysed.  
SEX DISTRIBUTION: (Table 1) 
Sex Frequency Percent (%) 
Female 1 13.3 
Male 14 93.7 
 
 
 
AGE OF STUDY POPULATION: 
                                                 Table 2 
Age Group (years) 
 
Numbers Percentage (%) 
10 – 20  
 
4 26.6 
20 – 30  
 
1 6.7 
30 – 40  
 
1 6.7 
40 – 50  
 
5 33.4 
50 – 60 
 
4 26.6 
 
 
 
  
Blood Groups: (Table 3) 
Blood Group Frequency  Percentage (%) 
1) A positive  6  40 
2) AB positive 1 6.7 
3) B positive 5 33.3 
4) O positive 3 20 
         Total 15 100 
 
 
 
 
 
INDICATIONS FOR LIVER TRANSPLANTATION: (Table 4) 
Diagnosis Frequency  Percentage (%) 
Alcoholic cirrhosis with DCLD 7 46.6 
Congenital biliary atresia 1 6.7 
Cryptogenic DCLD 2 13.3 
Hepatitis B virus related DCLD 1 6.7 
Hepatocellular carcinoma & Cirrhosis 1 6.7 
PFIC & DCLD 1 6.77 
Wilsons disease 2 13.3 
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DESCRIPTIVE STATISTICS OF RECIPIENT BEFORE SURGERY 
AND AFTER SURGERY: Table 5A                                                                                 
Datas Minimum Maximum Mean Standard 
Deviation 
Hemoglobin 9.00 12.00 10.3000 1.04881 
INR 1.80 3.00 2.4200 .35496 
Serum Creatinine 1.40 2.60 2.0200 .35697 
Total Bilirubin 90.00 190.00 136.0667 32.25671 
Direct Bilirubin 90.00 180.00 145.3333 30.17252 
AST 300.00 420.00 372.1333 32.35267 
ALT 1.80 4.20 2.9867 .66102 
ALP .50 2.00 1.2400 .42728 
Total Protein 9.00 12.00 10.5667 .94239 
Serum Albumin 5.00 6.80 5.9733 .50351 
Serum Globulin 3.60 5.50 4.5933 .58121 
 
Table 5B: 
Datas Minimum Maximum Mean Standard 
Deviation 
Hemoglobin 9 12 10 1.12 
INR 1.0 1.6 1.3 0.173 
Serum Creatinine .5 1.3 0.9 .249 
AST 32 50.0 41.5 5.655 
ALT 24 80.0 50.0 12.043 
ALP 160 280.0 228.0 37.291 
Total Bilirubin .7 1.9 1.1 0.267 
Direct Bilirubin .18 .40 .25 .0806 
Total Protein 4.8 7.0 6.0 0.729 
Serum Albumin 3.0 5.0 4.0 0.509 
Serum Globulin 0.6 2.9 1.9 0.541 
 
            Descriptive statistics of recipients before surgery and after surgery 
including Hemoglobin, Liver function test, serum creatinine and INR. They 
were raised before surgery and within normal limits after surgery.  
PROTROMBIN TIME OF RECIPIENT: (Table 6) 
Prothrombin 
Time(seconds) 
14 – 16 
  
17 - 19  
 
20 - 21  22 - 24  25 - 27  28 - 30  32 - 34 
Before 
surgery 
0 0 0 4 4 4 3 
After surgery 7 7 1 0 0 0 0 
 
 
 
 
 CULTURE OF DONOR BEFORE SURGERY:  
                                             (Table 7) 
Culture Donor Growth 
Throat swab culture/sensitivity 12 3 
Nasal swab culture/sensitivity 14 1 
Blood culture/sensitivity 15 NIL 
Urine culture/sensitivity 14 1 
 
 
 
 
CULTURE OF LIVER TRANSPLANT RECIPIENT BEFORE 
SURGERY: (Table 8) 
Culture Total Growth 
Throat swab culture/sensitivity 15 NIL 
Nasal swab culture/sensitivity 15 NIL 
Blood culture/sensitivity 15 NIL 
Urine culture/sensitivity 15 NIL 
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POST OPERATIVE INFECTIONS: 
Catheter Assosciated Urinary Tract Infections: (Table 9) 
Catheter Associated UTI Frequency Percentage (%) 
Escherichia coli 2 13.3 
Klebsiella pneumoniae 1 6.7 
Enterococcus faecalis  1 6.7 
Candida albicans 1 6.7 
Total 5 33.4 
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Antibiotic Sensitivity: (Table 9A) 
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Escherichia 
coli 1 
S R R R R S R S R S S S 
Escherichia 
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Amox.clav – Amoxicillin clavulanate 
 
Antibiotic Sensitivity of Gram positive Organism: (Table 9B) 
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SURGICAL SITE INFECTIONS: (TABLE 10) 
Organisms Frequency Percentage (%) 
Klebsiella pneumoniae 2 13.3 
Aspergillus fumigatus 1 6.7 
Total 3 20.0 
 
 
 
 
 
 
SURGICAL SITE INFECTIONS    : 
Antibiotic Sensitivity: (Table 10A) 
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SPUTUM CULTURE: (Table 11) 
Organisms Total Percent (%) 
Methicillin Resistant Staphylococcus aureus 
(MRSA) 
2 13.3 
No Growth 13 86.7 
 
 
  
 
Antibiotic Sensitivity: (Table 11A) 
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CENTRAL VENOUS TIP CULTURE: (Table 12) 
Organisms Frequency Percentage (%) 
Klebsiella pneumoniae 2 13.3 
Methicillin Resist. Staphylococcus aureus 2 13.3 
Total 4 26.6 
 
 
 
 
 
 
CENTRAL VENOUS TIP CULTURE: 
Antibiotic Sensitivity: (Table 12A) 
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Antibiotic Sensitivity of Gram Positive Organism: (Table 12B) 
 
 
Organism 
P
en
ic
il
li
n
 
C
o
tr
im
o
x
a
zo
le
 
C
ef
o
x
it
in
 
E
ry
th
ro
m
y
ci
n
 
C
li
n
d
a
m
y
ci
n
 
V
a
n
co
m
y
ci
n
 
L
in
ez
o
li
d
 
L
ev
o
fl
o
x
a
ci
n
 
T
ei
co
p
la
n
in
 
A
m
ik
a
ci
n
 
MRSA - 1 R R R S S S S R S S 
MRSA – 2 R S R S S S S S S S 
 
 
 
DRAINAGE FLUID CULTURE: (Table 13) 
Organisms Numbers Percentage (%) 
Klebsiella pneumoniae 1 6.7 
Methicillin Resistant Staphylococcus aureus 
(MRSA) 
1 6.7 
Total 2 13.4 
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DRAINAGE TUBE CULTURE: 
Antibiotic Sensitivity: (Table 13A) 
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Antibiotic Sensitivity of Gram Positive Organism: (Table 13B) 
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VIRAL INFECTION: (Table 14) 
Organism Number Percentage (%) 
Epstein-barr virus 1 6.7 
No infection 14 93.3 
 
  
 
FUNGAL INFECTIONS: (Table 15) 
Organism Number Percentage (%) 
Aspergillus fumigatus 1 6.7% 
Candida albicans 1 6.7% 
Total 2 13.4% 
 
 
 
  
 
 
IMMUNOSUPPRESSANTS ASSAY: (Table16) 
IMMUNOSUPPRESSANT ASSAY TOTAL 
Tacrolimus assay  11 
Cyclosporine assay   4 
Total  15 
         
 
  
                      In liver transplant patients, tacrolimus was given post- operatively 
along with corticosteroids to maintain immunosuppression. The trough level of 
tacrolimus was measured on alternate days. In about 15 patients, 4 patients 
developed increased blood sugar level and elevated liver enzymes due to 
tacrolimus. The trough level was also raised. So tacrolimus was stopped and 
changed to cyclosporine A to prevent the drug toxicity. Cyclosporine blood 
level was measured daily. The therapeutic reference range of cyclosporine A for 
liver transplant patient is 150 – 200 µg/ml for 6 months after liver transplant and 
100 – 150 µg/ml for > 6 months of transplantation. 
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                                           DISCUSSION 
           The incidence of infection in liver transplant recipients were analysed in 
our hospital, in about 15 patients during the study period. 
          The sex distribution is shown in Table 1. Among 15 patients in this study, 
one patient was female and the others were male. Liver disease is two-fold more 
common in males than females. 
60 
Hence the incidence of Liver transplant is 
more common in males which correlates in our study.    
         The age group patterns are shown in Table 2. The most common age 
group for liver transplantation is 40-60 years, who are more prone for liver 
diseases particularly in males due to alcoholism in accordance with Varma et 
al.
16
 
         The blood group distribution in our study is shown in Table 3. The 
common blood groups involved in liver transplantation were six A positive 
blood group and B positive blood group.  
        The indications for liver transplantation is shown in table in Table 4. The 
most common indication for liver transplantation is Alcoholic cirrhosis with 
decompensated liver diseases (46.7%) in accordance with Varma et al.
16
 After 
viral hepatitis, alcoholic liver disease is the second common indication for liver 
transplantation, overall in the United States and Europe. Alcoholic liver disease 
accounts for 17%-25% of all transplants performed in the United States and 
Europe. Without transplant, in patients with alcoholic liver disease, 5-year 
survival is as low as 23% which improves to 88% with transplantation. The 
1year, 5 years, and 10 years patient survival rates for alcoholic liver diseases 
were 96%, 88%, and 76% respectively, as compared to 97%, 80%, and 72% 
respectively, for patients with other indications for LT. Significantly better 
survival rates were observed for patients who remained abstinent when 
compared to those, who resumed drinking after LT. Further they observed that 
patients who resumed abusive drinking following LT had the lowest survival. 
Recurrent alcoholic liver disease was responsible for the majority of deaths 
(87.5%) among patients who resumed abusive drinking 
         Descriptive statistics of recipient before and after surgery is shown in 
Table 5A and 5B involving Hemoglobin, Liver Function test, Serum creatinine 
and INR (International Normalised Ratio). The results were increased before 
surgery and within normal limits after surgery. 
        Prothrombin time of recipients before surgery and after surgery, during 
discharge is shown in Table 6. It is prolonged before surgery due to liver 
diseases and normal, after surgery.  
        The cultures of donor before surgery are shown in Table 7, including 
Throat swab, Nasal swab, Blood culture and Urine Culture. Among 15 donors, 
β- hemolytic Streptococcal was isolated in Throat swab of 3 donors. Methicillin 
resistant Staphylococcus aureus was isolated from nasal swab of one donor. 
Candida albicans was isolated from Urine culture of one donor. 
            The culture of recipients before surgery is shown in Table 8. No growth 
was observed in Throat swab, Nasal swab, Blood culture and Urine culture 
before surgery. Coagulase negative Staphylococcus aureus (CONS) was 
isolated from nasal swab in most patients which were commensals. 
            Catheter assosciated Urinary tract infection of recipients is shown in 
Table 9 and it was 33.4% in this study. The most common organism isolated 
after transplantation was Escherichia coli. They belong to Extended spectrum β 
lactamases (ESBL) producing organism in accordance with Sang Il Kim.29 
Urinary tract infections are the common source of antibiotic resistant bacterias, 
such as extended spectrum β lactamases ( ESBL) producing Enterobacteriaceae, 
vancomycin resistant enterococci (VRE) and methicillin resistant 
Staphylococcus aureus (MRSA). Prolonged use of indwelling urinary catheter is 
one of the most common risk factor for UTI. The ESBL producing E. coli was 
confirmed by standard disk diffusion method in Muller Hinton agar, using 
cefotaxime and ceftazidime alone and in combination with clavulanate 
incubated at 37ᵒC for 16 – 18 hours. An increase in zone of diameter of ≥ 5mm 
was noticed for antimicrobial agent tested alone and in combination with 
clavulanate. Enterococcus infection was seen in 13.3% of patients and sensitive 
to norfloxacin, nitrofurantoin, vancomycin and linezolid. 
             Surgical site infection of liver transplant patients is shown in Table 10. 
The incidence of surgical site infection in this study is 20% in accordance with 
Sanger Il kim.
29
 In previous studies, the incidence of surgical site infections 
ranged from 9% to 21.5% as wound infection, from 6% to 18% as cholangitis, 
from 6.3% to 9% as peritonitis and from 4% to 12.9% as abscess. LT recipients 
differ from other transplant recipients with regard to underlying poor nutrition, 
bleeding tendencies, difficulties and longer surgical durations. The common 
organisms isolated in this study was, Klebsiella pneumonia (13.3%). The 
antibiotic sensitivity pattern shows that one organism is sensitive to Imipenem 
and resistant to Meropenem. The other organism (Klebsiella species) is a multi-
drug resistant, sensitive to Tigecycline and Colistin only. The surgical site 
infection, is the most common cause of bacterial infection and manifest itself 
early after liver transplantation. Treatment consists of surgical debridement and 
pathogen directed antimicrobial therapy.  
           Sputum culture positive organism of recipients is shown in Table 11. 
Bacterial pneumonia occurs in 13.3% of patients after transplantation which 
were caused by Methicillin Resistant Staphylococcus aureus in accordance with 
Sanger Il Kim.
29
 Antibiotic sensitivity pattern shows, one organism sensitive to 
Vancomycin, Linezolid and Teicoplanin. The other organism is sensitive to all 
except Penicillin and Cotrimoxazole. The sensitivity to Vancomycin was 
detected by minimum inhibitory concentration (MIC) by E- test method. Liver 
transplant recipients are more prone for respiratory tract infections because of 
prolonged surgical duration, frequent use of post-transplant mechanical 
ventilation and immunosuppression. In a study by Ikegami et al,
39
  gram 
negative bacilli were the predominant pathogens, causing up to 84% of bacterial 
pneumonia, and the short-term mortality rate was 42%.  Pathogen-specific 
antimicrobial therapy is done for the treatment of bacterial pneumonia, with or 
without reduction of immunosuppressive agents. After the immediate post-
operative period, the opportunistic bacterial pneumonia may occur less 
common. 
            Central venous tip culture of post liver recipient is shown in Table 12. 
The incidence of infection in this study is 26.6% and the most common 
organisms isolated are Methicillin resistant Staphylococcus aureus (13.3%) and 
Klebsiella pneumoniae (13.3%). Among the Klebsiella pneumoniae, one 
organism is sensitive to Imipenem and resistant to Meropenem. The MRSA 
isolates were sensitive to all drugs except penicillin. The sensitivity to 
Vancomycin was detected by MIC by E- test method. 
           Drainage tube culture of post liver transplant recipient is shown in Table 
13. The incidence is 13.4% in this study and caused by Klebsiella pneumoniae 
and Methicillin resistant Staphylococcus aureus (MRSA). The Antibiotic 
sensitivity pattern of Klebsiella pneumonia, shows that is sensitive to Imipenem, 
Tigecycline, Colistin and resistant to Meropenem. The MRSA organism was 
sensitive to Vancomycin, Linezolid, Teicoplanin and Levofloxacin. The 
sensitivity to Vancomycin was detected by MIC by E- test method. 
          The viral infection of post liver transplant recipient is shown in Table 14. 
It was seen in only one patient (6.7%), diagnosed as Epstein- barr virus with 
assosciated post-transplant lymphoproliferative disorder (PTLD). The patient 
reported to the hospital with complaints of fever, malaise and symptoms 
suggestive of lower respiratory tract infection, 4 months after transplantation. 
Blood investigations showed leucopenia, thrombocytopenia, anaemia and raised 
ESR. CT scan of thorax shows multiple mediastinal lymphadenopathy and CT 
scan of thorax and neck were normal. Real time PCR (Polymerase Chain 
Reaction) was done for Epstein-barr virus DNA and found to be to be positive. 
The patient was treated with chemotherapy with reduction of 
immunosuppression. 
            The fungal infection of post liver transplant recipient is shown in Table 
15. It was seen in 13.4% of patients. The organisms isolated were Candida 
albicans from catheter assosciated urinary tract and Aspergillus fumigatus from 
wound tissue. In accordance with Pappas PG and Silveria FP, Candida species 
accounts for over half of all invasive fungal infections in liver recipients. 
Superficial and invasive candidiasis occurs early and often during the first 1-3 
months after liver transplantation.
50
 Invasive candidiasis could be primary or 
secondary to infected catheters or surgical wounds. The American Society of 
Transplantation recommends antifungal prophylaxis against Candida to high-
risk liver transplant recipients with many centres providing it for 4 
weeks.
1
Aspergillus species is the second most common fungal infection in liver 
recipients, with invasive aspergillosis occurring in 1%-9.2%. Antifungal 
prophylaxis against Aspergillus species could result in reduction in superficial 
and invasive infection, as well as the mortality. The current guidelines 
recommend voriconazole as the first line of treatment for 12 weeks. Surgical 
excision or debridement remains an integral part of the management of invasive 
aspergillosis.
1
 
              The immunosuppressant assay is shown in Table 16. In liver transplant 
patients, tacrolimus was given post- operatively along with corticosteroids. The 
tacrolimus trough level was measured on alternate days to maintain 
immunosuppression. In about 15 patients, 4 patients developed increased blood 
sugar level and elevated liver enymes due to tacrolimus about 3- 4 days after 
transplantation. The trough level of tacrolimus were also raised. The drug was 
stopped and changed to cyclosporine A to prevent the drug toxicity. 
Cyclosporine A blood level were measured in 4 patients. In most centres, 
tacrolimus is preferred over cyclosporine because of its greater potency and 
organ protective effects. It is usually started with a low dose of 0.1- 0.15 mg/kg 
per day divided in 2 doses, orally on the first day after transplant and the dose is 
gradually increased to reach the desired trough level. Usually, the levels of 10-
15 ng/ml were targeted for the first 4-6 weeks and 5-10 ng/ml were accepted 
thereafter by many centres to prevent acute rejections and renal protection.
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When cyclosporine A has to be used, the recommended dose is 10-15 mg/kg per 
day in 2 divided doses. The trough level (C0 level) in the early post-transplant 
period, is 250 µg/ml and 150 µg/ml later on. For cyclosporine, C2 levels (2 hour 
after dose) monitoring has also been implemented at some centres. The C2 level 
may be in the range of 800-1400 µg/ml for the first 3 months, 600-1000 µg/ml 
after 6 months and 500-700 µg/ml after 1-year post transplantation.
57
  
           Acute graft rejections were seen in 3 patients (20%) after liver 
transplantation and were treated with high dose (intravenous) corticosteroids for 
3 – 5 days (Pulse therapy) in combination with immunosuppressants, according 
to Jens encke et al. The typical dosage of Methyl prednisolone is 500 or 
1000mg for 3 days and gradually tapered to oral prednisolone. Acute rejection 
occurs 5 – 15 days after liver transplantation. It is clinically suspected by 
elevation in serum aminotransferase and alkaline phosphatses which typically 
preceeds jaundice and fever. Diagnosis should be confirmed by liver biopsy 
prior to initiation of treatment for rejection. Approximately 75% of episodes of 
acute cellular rejection resolve after a course of high dose corticosteroids (3 – 5 
days of 500 -1000 mg of Methyl prednisolone) and a second course is effective 
in additional 10% of cases. Monoclonal antibodies (Muromonab) seems to be 
beneficial in steroid resistant rejections.
58
  
             Bacterial pathogens differ between the post-transplant period. Most of 
the bacterial infections occur within 2 months of transplantation. Enteric gram 
negative bacilli and gram positive cocci are the major causative organisms. 
Enterobacteriaceae are the major pathogens in Liver transplant recipients. The 
gram negative bacteria can also cause surgical site infections including deep 
intra-abdominal infections, bacteremia, pneumonia, urinary tract infections and 
catheter-related infections. Enterobacteriaceae are the major pathogens in liver 
tranplant recipients in this study and a high rate of drug-resistant were seen.  
The prevalence of ESBL producing gram negative bacilli, carbapenem-resistant 
klebsiella pneumoniae (CRKP), multi-drug resistant Acinetobacter and  
Pseudomonas are increasing and are related to higher rates of treatment 
failure.
59
 The risk factors for multi-drug resistant gram negative bacilli (MDR-
GNB) infections include, prolonged hospitalization, antibiotic exposure, 
surgical complications and the need for invasive devices and are associated with 
increased rates of allograft failure and mortality.  
                  The gram positive bacteria are the major cause of superficial and 
deep surgical site infections, bacteremia and pneumonia, predominantly during 
the first 2 months after LT. They are the most common causes of early post-
transplant surgical site and bloodstream infections. Among the gram positive 
bacteria, the common organisms include Staphylococci, Streptococci and 
Enterococci. The incidence of Methicillin resistant Staphylococcus aureus 
(MRSA) were more common in this study and were sensitive to vancomycin, 
linezolid and teicoplanin. Enterococcus faecalis infection was found in catheter 
assosciated urinary tract and sensitive to norfloxacin, nitrofurantoin, 
vancomycin and linezolid. 
                                             
 
 
 
 
 
 
 
 
 
 
  
 
                                                 SUMMARY 
 Out of 15 Liver Transplant patients in this prospective study, 14 patients 
were male and one patient was female. 
 The most common age group was between 40 – 50 years. 
 The most common indication for Liver transplantation was Alcoholic 
cirrhosis with decompensated liver disease and it is 46.6% in this study. 
 The common organism isolated in catheter assosciated urinary tract 
infection was Escherichia coli and was 13.3% in this study. They were 
ESBL producing organism. 
 Surgical site infections were caused by Klebsiella pneumoniae during 
the post- operative period. They are multi drug resistant, with sensitivity 
to Imipenem, Tigecycline and Colistin. and it was 13.3% in this study. 
 Bacterial pneumonia was seen in 13.3% of patients and was caused by 
Methicillin resistant Staphylococcus aureus (MRSA) with sensitivity to 
Vancomycin, Linezolid and Teicoplanin. 
 Central venous tip culture shows growth in 26.6% of patients, the 
isolates were Klebsiella pneumoniae and Methicillin resistant 
Staphylococcus aureus.  
 Drainage tube culture was positive in 13.4% of patients, caused by 
Klebsiella pneumoniae and Methicillin resistant Staphylococcus aureus. 
The Klebsiella pneumoniae was multi-drug resistant, sensitive to 
Tigecycline and Colistin. The MRSA isolate was sensitive to 
Vancomycin, Linezolid and Teicoplanin. 
 Viral infection was seen in one patient, diagnosed as Epstein-barr virus 
assosciated post-transplant lymphoproliferative disorder. 
 Fungal infection was seen in 13.4% of patients. The isolates were 
Candida albicans from catheter assosciated urinary tract and Aspergillus 
fumigatus from wound . They were treated with antifungal drugs. 
Surgical wound debridement was done for aspergillus fumigatus 
infection.  
 Acute graft rejections were seen in 3 patients (20%) after liver 
transplantation and were treated with high dose steroids (intravenous 
methyl prednisolone) for 3-5 days.   
 Bacterial infections were more common in the post-operative period in 
this study. The infections due to gram negative organisms were common 
when compared to gram positive organisms. Most of the organisms 
isolated were multidrug resistant.   
        
            
 
 
                                             CONCLUSION 
 A study on the incidence of infections was done in 15 liver transplant 
patients, during the study period October 20l6 – July 2017 and the role 
of immunosuppressants on immunosuppression studied. 
 Alcoholic cirrhosis with decompensated liver disease was the most 
common indication for liver transplantation and was seen in 46.6% of 
patients. 
 Catheter assosciated urinary tract infection was seen in 5 patients. They 
are commonly caused by Escherichia coli and are ESBL producers. 
 Surgical site infections were seen in 13.3% of patients, caused by 
Klebsiella pneumoniae. They are multi-drug resistant and treated with 
Imipenem, Tigecycline and Colistin. 
 Bacterial pneumonia was seen in 13.3% of patients, caused by 
Methicillin resistant Staphylococcus aureus (MRSA). They are sensitive 
to Vancomycin, Linezolid and Teicoplanin.  
 Central venous tip culture was positive in 26.6% of patients, caused by 
Klebsiella pneumoniae and Methicillin resistant Staphylococcus aureus. 
 Drainage tube culture was positive in 13.3% of patients, caused by 
Klebsiella pneumoniae and Methicillin resistant Staphylococcus aureus 
(MRSA). Klebsiella pneumoniae was multidrug resistant with sensitivity 
to Tigecycline and Colistin only. MRSA was sensitive to Vancomycin, 
Linezolid and Teicoplanin. 
 Fungal infections were caused by Candida albicans from catheter 
assosciated urinary tract and Aspergillus fumigatus from surgical 
wound. They were seen in 13.3% of patients and treated with anti- 
fungal drugs. 
 Viral infection was seen in one patient, diagnosed as Epstein-barr virus 
assosciated with post-transplant lymphoproliferative disorder (PTLD). 
 Acute graft rejections were seen in 3 (20%) patients and were treated 
with high dose intravenous corticosteroids, Methyl prednisolone 500 or 
1000mg for 3 – 5 days (Pulse therapy). 
 Infections after liver transplantation are the common cause of morbidity 
and mortality. Evaluation of common nosocomial infection and 
avoidance of unnecessary indwelling catheters can prevent early 
morbidity. Frequent use of antibiotics prior to surgery for varying 
indications (e.g. infection and SBP prophylaxis) render liver transplant 
recipients vulnerable to multi-drug resistant strains of bacteria 
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                                                 PROFORMA 
 
Name :                                                                                                   Serial No. 
Age :                                                                             DOA - 
Sex :                                                                              DOS -  
IP. No :                                                                          DOD - 
Provisional Diagnosis:  
HISTORY DETAILS: 
 
6) H/O pain over the wound site              (Yes/No) 
7) H/O discharge from the wound site     (Yes/No) 
8) H/O fever or any other symptoms        (Yes/No) 
9) H/O intra operative complications        (Yes/No) 
10) H/O antibiotics and immuno-              (Yes/No) 
     Suppressants during the 
     Post-operative period 
11) H/O comorbid illness                           (Yes/No) 
 
GENERAL EXAMINATION: 
Anaemia                                                        (Yes/No) 
Jaundice                                                        (Yes/No) 
Pedal edema                                                 (Yes/No) 
 
 
 
SYSTEMIC EXAMINATION: 
RESPIRATORY SYSTEM: 
CARDIOVASCULAR SYSTEM: 
PER ABDOMEN: 
CENTRAL NERVOUS SYSTEM: 
 
INVESTIGATIONS: 
 
 
 
 
 
POST- OPERATIVE PERIOD: 
Antibiotics and Immunosuppressants course: 
 
 
 
ADVICE:                  
 
 
  
                                       KEY TO MASTER CHART 
IP.NO. - Inpatient number 
DCLD – Decompensated Liver  Diseases 
HCC – Hepatocellular carcinoma 
HBV – Hepatitis B virus 
PFIC – Progressive Familial Intrahepatic Cholestasis 
Total WBC Count – Total White Blood Cell Count 
E/ B/ M – Eosinophils/ Basinophils/ Monocytes 
RBC Count – Red Blood Cell Count 
PCV – Packed Cell Volume 
MCV – Mean Corpuscular Volume 
MCH – Mean Corpuscular Haemoglobin 
MCHC – Mean Corpuscular Haemoglobin Concentration 
Hb – Hemoglobin 
PT – Prothrombin time 
INR – International Normalised Ratio 
Sr. creat. – Serum creatinine 
AST – Aspartate transaminase 
ALT – Alanine transaminase 
ALP – Alkaline phosphatase 
Total BR – Total bilirubin 
Direct BR – Direct bilibubin 
Na – Sodium 
K – Potassium 
Cl – Chloride 
Ca – Calcium 
Mg – Magnesium 
P – Phosphorus 
c/s – culture / sensitivity 
MRSA – Methicillin Resistant Staphylococcus aureus 
UTI – Urinary tract Infection 
CV TIP – Central venous tip 
DT Fluid – Drainage tube fluid 
E.coli – Escherichia coli 
Kleb. Pneumonia – Klebsiella pneumonia 
EBV – Epstein barr virus 
Ak – Amikacin 
G – Gentamycin 
NIT – Nitrofurantoin 
Nor – Norfloxacin 
Cz – Cefazolin 
IMP – Imipenem 
MRP – Meropenem 
AmxC – Amoxicillin Clavulanic acid 
Ba – Cotrimoxazole 
Ctx – Cefotaxime 
Cip – Ciprofloxacin 
Levo – Levofloxacin 
Amp – Ampicillin 
TGC – Tigecycline 
Colis – Colistin 
HLG – High level gentamycin 
Dox – Doxycycline 
Pen – Penicillin 
Ery – Erythromycin 
CD – Clindamycin 
Van – Vancomycin 
Lz – Linezolid 
Teico – Teicoplanin 
 
 SENTHIL VELAN URINE C/S 
 
 
RAMAR URINE C/S 
 
 
SUBRAMANI  URINE C/S 
 
 
ESBL PRODUCING E.coli (Ramar) 
 
 
 
 
 
ESBL PRODUCING E.coli (Subramaniam) 
 
 
 
 
 
 
 
  
SAMPATH SPUTUM C/S 
 
 
 
 
RAGUPATHI CV TIP C/S 
 
 
 
 
 
 
 
 
 
 
 
 
 
VANCOMYCIN MIC – Staphylococcus Aureus 
 
 
 
CANDIDA ALBICANS – URINE (GRAM STAIN) 
 
 
 
 
 
ASPERIGILLUS FUMIGATUS – HPE SLIDE 
 
 
S.No. Category Name IP.NO. Age/Sex Blood group Diagnosis Platelet count Total WBC count Differential count RBC count PCV MCV MCH MCHC Hb PT /sec INR Bd.Sugar
cells/cu.mm cells/cu.mm Neutrop. Lymphoc. E/B/Mon million/µl FI pg g/dl g/dl mg/dl
1 Donor Mohan 1651076 45/M A +VE 200000 9400 70% 24% 6% 4million 40% 84FI 28pg 36g/dl 10 14-16sc 1.4 140
Recipient Sampath 1651032 58/M A +VE Alcoholic cirrhosis & DCLD 180000 7800 80% 18% 2% 3.8million 34% 80FI 26pg 30g/dl 9 12-14sec 1.2 124
2 Donor Chitra 1656160 38/F A +VE 220000 10400 74% 22% 4% 3.8million 36% 84FI 30pg 32g/dl 11 14-16sec 1.4 136
Recipient Arun kumar 1656125 18/M A +VE Wilsons disease 190000 9000 76% 20% 4% 3.6million 34% 80FI 28pg 30g/dl 11 14-16sec 1.4 105
3 Donor Sumathi 1660125 36/F B +VE 190000 9600 68% 30% 2% 5million 42% 90FI 36pg 42g/dl 14 12-14sec 1.2 110
Recipient Ramar 1660086 45/M B +VE Alcoholic cirrhosis & DCLD 214000 8100 84% 14% 2% 4.2million 38% 86FI 34pg 30g/dl 10 16-18sec 1.6 136
4 Donor Pradeep 1671605 27/M O+VE 180000 8600 70% 26% 4% 4.2million 40% 86FI 38pg 42g/dl 10 12-14sec 1.2 96
Recipient Ravichandran 1671576 43/M  O +VE Alcoholic cirrhosis & DCLD 166000 9600 76% 18% 6% 3.2million 30% 80FI 30pg 34g/dl 9 14-16sec 1.4 140
5 Donor Murugesan 1668625 48/M O +VE 220000 10600 70% 24% 6% 4.6million 42% 88FI 36pg 38g/dl 12 16-18sec 1.6 125
Recipient Subramaniam 1668591 57/M O +VE Cryptogenic DCLD 214000 8700 86% 12% 2% 3.8million 34% 80FI 28pg 32g/dl 10 14-16sec 1.4 160
6 Donor Krishnakumar 1708536 36/M A +VE 240000 9600 68% 26% 6% 4million 40% 85FI 38pg 40g/dl 10 14-16sec 1.4 100
Recipient Udayakumar 1708510 36/M A +VE HCC& Cirrhosis 220000 11000 78% 28% 2% 3.6million 35% 82FI 30pg 34g/dl 9 12-14sec 1.2 121
7 Donor Baskar 1709840 30/M B +VE 190000 9800 76% 20% 4% 5.2million 42% 80FI 38pg 42g/dl 14 12-14sec 1.2 90
Recipient Senthilvelan 1709826 42/M B +VE Alcoholic cirrhosis & DCLD 180000 6400 66% 24% 10% 4million 36% 76FI 26pg 34g/dl 10 14-16sec 1.4 106
8 Donor Rajkumar 1717446 45/M A +VE 220000 11000 78% 28% 4% 5.4million 40% 85FI 36pg 42g/dl 14 14-16sec 1.4 160
Recipient Krishnan 1717429 54/M A +VE Cryptogenic DCLD 190000 8400 84% 11% 5% 3million 30% 78FI 32pg 36g/dl 9 12-14sec 1.2 120
9 Donor Rajasekar 1632545 55/M A +VE 210000 8500 70% 26% 4% 4.6million 42% 82FI 34pg 40g/dl 12 16-18sec 1.6 145
Recipient Raguraman 1632533 47/M A +VE Alcoholic cirrhosis & DCLD 246000 11400 74% 16% 10% 3.5million 32% 80FI 28pg 32g/dl 9 14-16sec 1.4 120
10 Donor Saranya 1637594 27/F B +VE 210000 10200 76% 28% 6% 3.6million 36% 80FI 34pg 40g/dl 10 14-16sec 1.4 102
Recipient Arthi 1637570 20/F B +VE Wilsons disease 180000 7800 80% 16% 4% 2.8million 28% 78FI 28pg 34g/dl 9 12-14sec 1.2 130
11 Donor Durairaj 1734442 36/M AB +VE 190000 9000 70% 26% 4% 4million 40% 84FI 36pg 42g/dl 11 12-14sec 1.2 116
Recipient Radha  Krishnan 1734429 53/M AB +VE Alcoholic cirrhosis & DCLD 160000 5800 73% 21% 6% 3.6million 30% 74FI 30pg 34g/dl 10 14-16sec 1.4 140
12 Donor Bhoopesh kumar 1738696 36/M O +VE 180000 10400 76% 30% 4% 5.4million 42% 82FI 36pg 42g/dl 14 14-16sec 1.4 96
Recipient Abinesh 1738671 18/M O +VE Congenital biliary atresia 115000 8100 60% 32% 7% 3.8million 35% 80FI 30pg 34g/dl 10 12-15sec 1.2 92
13 Donor Irudhayaraj 1741204 50/M B +VE 225000 9600 68% 30% 2% 5million 42% 80FI 36pg 40g/dl 14 14-16sec 1.4 156
Recipient Gopala Krishnan 1741191 43/M B +VE Alcoholic cirrhosis & DCLD 166000 6400 62% 26% 12% 3.4milli0n 30% 74FI 32pg 36g/dl 9 16-18sec 1.6 162
14 Donor Anand 1744910 42/M B +VE 240000 11200 78% 20% 2% 5.2million 42% 86FI 36pg 42g/dl 14 16-18sec 1.6 124
Recipient Ragupathi 1744884 28/M B +VE HBV related DCLD 208000 9000 73% 17% 10% 3.9million 36% 80FI 32pg 36g/dl 10g/dl 12-14sec 1 110
15 Donor Dhanushkodi 1749425 18/M A +VE 210000 8400 74% 30% 6% 4.2million 40% 85FI 36pg 42g/dl 10g/dl 12-14sec 1.2 92
Recipient Alwin deepak 1749406 18/M A +VE PFIC & DCLD 180000 5400 72% 24% 4% 3.6million 32% 80FI 30pg 34g/dl 10 14-16sec 1.4 100
Urea Sr.Creat. Liver Function Test Electrolytes: Culture of Donor & Recipient Before Surgery
mg/dl mg/dl Total BR Direct BR AST ALT ALP Total Protein Albumin Globulin Na K Cl Ca Mg P Throat swab c/s Nasal swab c/s Blood c/s Urine  c/s
mg/dl mg/dl µ/dl µ/dl µ/dl g/dl g/dl g/dl mEq/L mEq/L mEq/L mg/dl mg/dl mg/dl
28 0.8 1 0.2 45 44 140 5.5 3.5 2 140 4.5 102 9 4 2.5 NO GROWTH NO GROWTH NO GROWTH NO GROWTH
34 1 1 0.2 50 48 250 6 4.5 1.5 145 4 109 10 2.8 2 NO GROWTH NO GROWTH NO GROWTH NO GROWTH
32 1 1.2 0.2 50 50 160 5.6 3.6 2 138 4.5 100 11 3.5 2 NO GROWTH NO GROWTH NO GROWTH NO GROWTH
36 0.9 1 0.2 42 54 215 6.5 4.5 2 150 5 110 10 2.5 2 NO GROWTH NO GROWTH NO GROWTH NO GROWTH
24 0.8 1 0.2 40 48 170 6 4 2 140 5 98 10 4 2.5 β-Streptococci NO GROWTH NO GROWTH NO GROWTH
22 1.2 1.2 0.4 45 50 260 5 4.4 0.6 137 4.8 104 10 2.4 2 NO GROWTH NO GROWTH NO GROWTH NO GROWTH
34 0.9 1 0.2 40 40 154 5.4 3.4 2 145 5 98 10 4 2 NO GROWTH NO GROWTH NO GROWTH NO GROWTH
30 1.2 1.15 0.4 35 55 210 5.8 3.6 2.2 142 4.3 108 9 2 1.8 NO GROWTH NO GROWTH NO GROWTH NO GROWTH
30 1 1.2 0.2 46 38 145 5 3 2 138 4.5 102 9 4.2 1.8 NO GROWTH MRSA NO GROWTH NO GROWTH
28 1.02 1.08 0.2 45 54 220 4.8 3 1.8 143 3.2 98 8.5 2.2 1.9 NO GROWTH NO GROWTH NO GROWTH NO GROWTH
36 0.8 1 0.2 36 160 5 3 2 140 4.5 106 11 4.8 1.9 NO GROWTH NO GROWTH NO GROWTH NO GROWTH
32 0.9 1.2 0.2 50 35 180 6.5 4.2 2.3 142 4 103 10 2.4 1.7 NO GROWTH NO GROWTH NO GROWTH NO GROWTH
28 1 1.2 0.2 42 120 5.5 3.5 2.5 142 5 100 11 3.8 2 NO GROWTH NO GROWTH NO GROWTH NO GROWTH
26 1.2 0.7 0.26 38 44 160 6.8 4.5 2.3 135 4.8 95 10 2.4 1.7 NO GROWTH NO GROWTH NO GROWTH NO GROWTH
34 0.8 1 0.2 40 40 180 6 4 2 136 4.5 104 10 3.6 2.5 NO GROWTH NO GROWTH NO GROWTH NO GROWTH
32 1.2 0.8 0.2 32 45 260 6.2 4.3 1.9 130.5 5 99 9 2.3 2 NO GROWTH NO GROWTH NO GROWTH NO GROWTH
32 0.8 0.8 0.2 42 42 180 5 3 2 140 5 106 10 3.6 2 NO GROWTH NO GROWTH NO GROWTH NO GROWTH
30 0.8 1.2 0.4 45 40 240 5.6 3.7 1.9 136 4.6 102 9 2.3 1.6 NO GROWTH NO GROWTH NO GROWTH NO GROWTH
34 0.7 1 0.2 45 42 190 6 4 2 138 4.5 100 11 3.8 2.5 β-Streptococci NO GROWTH NO GROWTH NO GROWTH
30 0.68 1.2 0.2 40 50 260 5 3.6 1.4 135 4.3 106 10 2.4 1.6 NO GROWTH NO GROWTH NO GROWTH NO GROWTH
28 1 0.9 0.2 40 46 160 5 3 2 140 4.5 102 10 4 2 NO GROWTH NO GROWTH NO GROWTH NO GROWTH
32 1.09 1.02 0.22 46 80 246 7 4.1 2.9 134 4 109 9.6 2.4 1.8 NO GROWTH NO GROWTH NO GROWTH NO GROWTH
26 1 1 0.2 38 40 176 5.5 3.5 2 145 4.5 104 11 4.2 2.5 β-Streptococci NO GROWTH NO GROWTH NO GROWTH
28 0.8 0.95 0.18 40 24 194 7 5 2 140 4.2 100 10 2.2 2 NO GROWTH NO GROWTH NO GROWTH NO GROWTH
34 1 0.9 0.2 50 50 150 6 4 2 138 5 106 10 4.4 2 NO GROWTH NO GROWTH NO GROWTH NO GROWTH
30 0.8 1.2 0.25 35 38 178 6.5 4 2.5 136.5 4.6 101.2 10 2.5 1.6 NO GROWTH NO GROWTH NO GROWTH NO GROWTH
38 0.8 0.8 0.2 45 48 180 5 3 2 145 5 102 11 3.8 2.5 NO GROWTH NO GROWTH NO GROWTH NO GROWTH
34 0.9 1.2 0.25 35 55 268 5.4 3.7 1.7 142 4.8 98 11 2.5 2 NO GROWTH NO GROWTH NO GROWTH NO GROWTH
34 0.8 0.9 0.2 40 45 160 5.5 3.5 2.5 145 5 106 11 3.6 2.4 NO GROWTH NO GROWTH NO GROWTH NO GROWTH
28 0.8 1 0.2 45 50 280 6 4.5 1.5 138 4 103 11 2 1.9 NO GROWTH NO GROWTH NO GROWTH NO GROWTH
RECIPIENT, Post Operative Infections
Catheter Assos. UTI Sputum culture c/s Central Venous Tip c/s Drainage Fluid c/s Wound swab c/s Viral Infection Fungal Infections
NO GROWTH MRSA,S-Ak,G,Ba,Van,Lz,Teico,Levo NO GROWTH                                    -                       -              -                    -
R-Pen,Ery,CD,Cip  
NO GROWTH NO GROWTH NO GROWTH                                      -                        - EBV Positive                   -
E.coli, S- AK,NIT,IMP,AmxC,TGC,Colis NO GROWTH Kleb.pneum,S- Ak,Gen,IMP,TGC,Colis                                      - Kleb.pneum, S- Ak,Gen,IMP,TGC,Colis              -                    -
R-G,PT,LZ,MRP,Ba,Nor,Cip,Ctx R-MRP,Ba,Cip,Ctx R-MRP,Ba,Cip,Ctx,Cpm
NO GROWTH NO GROWTH NO GROWTH Rt.- MRSA,S-Ba,Ak,G,Van,Lz; R-Pen,Ery,CD Aspergillus fumigatus              - Aspergillus fumigatus
Lt.-Kleb.pneum,S-IMP; R-Ak,G,Cip,Ctx,MRP
E.coli,S-Ak,Gen,NIT,IMP,AmxC,TGC,Colis MRSA-Ak,G,Ery,CD,Van,Lz,Teico MRSA,S-Ak,G,Ery,CD,Van,Lz,Teico                                      - Kleb.pneum, S-TGC,Colistin              -                      -
R- Ba,Ctx,CZ,Nor,Cip, Amp R-Pen,Ba,Levo R-Ba,Levo R-Ak,G,Ctx.Cz,Ba,Cip,IMP,MRP
NO GROWTH NO GROWTH NO GROWTH                                    -                         -               -                     -
Kleb.pneum,S-Ak,G,NIT,IMP,TGC,Colis NO GROWTH NO GROWTH                                     -                          -               -                       -
R-PT,Ba,MRP,Cip,Ctx,Cpm
NO GROWTH NO GROWTH NO GROWTH                                      -                           -               -                       -
NO GROWTH NO GROWTH NO GROWTH                                        -                           -              -                      -
NO GROWTH NO GROWTH Kleb.pneum,S-Ak,G,Cip,IMP,MRP,TGC, Colis                                        -                            -               -                      -
R-Ba,Ctx,Cz
NO GROWTH NO GROWTH NO GROWTH                                        -                             -               -                      -
Candida albicans NO GROWTH NO GROWTH                                       -                             -                - Candida albicans
NO GROWTH NO GROWTH NO GROWTH                                         -                               -              -                       -
Entero. Faecalis,S- Amp,HLG,NIT,Nor,Van,Lz NO GROWTH MRSA-Ery,CD,Ba,Cip,Van,Lz,Teico,Levo                                          -                              -               -                      -
R- Pen,Dox R- Pen
NO GROWTH NO GROWTH NO GROWTH                                            -                                -              -                       -
